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Abstract 
Purpose: To evaluate the effectiveness of platelet rich plasma (PRP) in musculoskeletal 
pathologies. 
Methods: We completed a review of the literature on the use of PRP in tendon, muscle, 
bone, and intra-articular pathologies (Chapter 2). We completed a systematic review and 
meta-analysis on the effectiveness of PRP in ultrasound guided versus palpation guided 
injections of PRP in non-operative treatment of tendon and muscle pathologies using an 
indirect analysis method (Chapter 3). We conducted a randomized controlled trial to 
determine the effectiveness of PRP versus corticosteroid (CS) injections in patients with 
plantar fasciitis (Chapter 4).  
 Results: Most studies evaluating the effectiveness of PRP in musculoskeletal pathologies are for 
the treatment of tendon and intra-articular pathologies, with fewer studies assessing its 
effectiveness in muscle and bone healing. The published studies included in the review had a 
heterogenous summation of results that could not be used to conclusively determine the 
superiority of PRP over other treatments for musculoskeletal pathologies. We included 26 
studies in our systematic review to compare ultrasound versus palpation guided injections of 
PRP. We found no statistically significant difference between ultrasound versus palpation guided 
injections for failure rates and pain outcomes at two months, two to three months, and six months 
following injection (p > 0.05). The comparison of functional outcomes at six months showed a 
significant effect in favor of palpation guided injections (p = 0.01), but heterogeneity of the 
analysis was high (I2 = 83.5%) and we were unable to make any definitive conclusions on the 
results. In our RCT, we found no statistically significant difference between PRP versus CS 
injections for our primary outcome of pain and function using the American Orthopaedic Foot 
and Ankle Society Ankle-hindfoot scale, at six months or one year. We also found no 
statistically significant difference for all other outcomes at six months and one year.    
Conclusion: The results in all three of our studies do not provide supporting evidence for the 
superior effectiveness of PRP injections in musculoskeletal pathologies. There are currently no 
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clear indications for the clinical use of PRP injections in musculoskeletal pathologies and further 
research is needed in this area. 
Keywords: Platelet rich plasma, musculoskeletal pathologies, ultrasound guided injections, 
palpation guided injections, tendon, muscle, bone, intra-articular, ligament, plantar fasciitis, 
corticosteroid injections 
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Preface 
Conception of the research questions came from collaboration with my supervisors Dr Kevin 
Willits, through his clinical practice as a fellowship trained orthopaedic surgeon, and Dr Dianne 
Bryant, who is a health research methodologist. I was solely responsible for the literature search 
and structuring of the first draft of the review paper which was then edited by my supervisors 
prior to submission for publication. Under the guidance of Dr Bryant, I created the protocol for 
the systematic review and meta-analysis. I enlisted the assistance of my colleagues Laura 
Churchill (PhD student) and Alliya Remtulla (PhD student) to serve as independent reviewers in 
the literature search, study quality rating, and data extraction. I was solely responsible for the 
statistical data analysis and writing of the first draft of the manuscript. The manuscript was 
circulated for feedback between the independent reviewers and my supervisors prior to 
submission. The randomized controlled trial was designed by my supervisors and Lyndsay 
O’Brecht, a master’s student under the supervision of my current supervisors. Lyndsay recruited 
the first 26 patients and I recruited an additional 88 patients. I was responsible for data 
collection, data analysis, and the first draft of the manuscript which was circulated for feedback 
to my supervisors prior to submission.      
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Chapter 1 Introduction 
The overall purpose of this thesis was to evaluate the effectiveness of platelet rich plasma (PRP) 
as a treatment for musculoskeletal pathologies.  PRP was introduced in the late 1990’s in the oral 
and maxillofacial field but the demand for PRP in sports medicine took off in 2009, largely 
fueled by the media when Hines Ward and Troy Polamalu of the Pittsburgh Stealers used PRP 
for their sports pathologies prior to the team winning the NFL Superbowl.  Since then the 
number of published studies has grown.    
PRP is a concentrated volume of human platelets suspended in plasma66. PRP is obtained when 
whole blood from an individual is spun in a centrifuge to separate the blood into its components 
(plasma, leukocytes, platelets and red blood cells) before drawing the plasma, platelets (and 
potentially leukocytes) from the solution and injecting it into the injury site. The theory behind 
the effectiveness of PRP is that the elevated concentration of growth-factor-releasing platelets 
will improve tissue healing.  
Platelets release growth factors that are responsible for the anabolic (tissue building) processes 
involved in tissue healing. The most common growth factors found in PRP include platelet-
derived epidermal growth factor (PD-EGF), platelet-derived growth factor (PDGF) A and B, 
transforming growth factor (TGF-β1), insulin-like growth factor (IGF-I, II), vascular endothelial 
growth factor (VEGF), endothelial cell growth factor (ECGF), and basic fibroblast growth factor 
(bFGF)28.  
The concentration of platelets found in PRP compared to whole blood varies between each 
system and by individual; from being similar to the concentration found at time of blood draw to 
up to 8 times the concentration.  With differences in platelet concentration it makes sense that 
there is also a variation in the concentration of growth factors and other bioactive components 
responsible for tissue healing.  It is important to note however, that a positive association 
between increased platelet count and the concentration of growth factors present in a PRP 
solution remains unproven as does the association between concentration and healing. 
Platelets are activated and begin secretion of the growth factors when the clotting mechanism of 
blood begins. The secretion of the growth factors naturally begins within 10 minutes of clotting, 
and 95% of the growth factors are released within 1 hour of activation67. Some systems 
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encourage the use of activators such as thrombin, to activate the platelets and begin the secretion 
of growth factors upon application of the PRP solution to the injured area. Others rely on the 
natural clotting mechanism for the activation process of the platelets13,24,69,109.  Most systems also 
promote the addition of an anticoagulant, preferably anticoagulant citrate dextrose solution A 
(ACD-A) or sodium citrate13, to prevent early clotting and enhance growth factor function.  
The consensus of the ideal speed, force, and spin procedure (i.e. single versus double spin) for 
centrifugation continues to be debated and more research is needed to compare the clinical 
effectiveness of the solutions produced by each to conclusively determine superior effectiveness 
amongst preparation systems. 
In summary, the volume of good quality evidence in support of PRP is small and diluted by the 
heterogeneity amongst studies caused by differences in the composition of PRP.  Specifically, 
there are a number of commercial systems available from industry and each system has a unique 
protocol for the preparation and administration of the PRP solution to the injured tissue 
(Appendix 1). Variations include the amount of blood drawn, whether to add an anticoagulant, 
the spin time and speed of the centrifuge, whether to add an activator, and whether the resultant 
PRP solution should include leukocytes  
The thesis consists of three chapters. Our first chapter is a published systematized review of the 
literature37 evaluating the effectiveness of PRP in muscle, tendon, cartilage, bone and intra-
articular applications for musculoskeletal pathologies in humans (permission in Appendix 2) . 
We also summarized the results of systematic reviews comparing studies that evaluate the use of 
PRP in orthopaedic bone and soft tissue pathologies, and in arthroscopic rotator cuff repair.  
Next, because some have argued that the effectiveness of PRP in musculoskeletal pathologies 
may be hindered by the inaccurate injection of the treatment into the target tissue31,110, our 
second chapter is a systematic review and meta-analysis to compare the effectiveness of 
ultrasound-guided versus palpation alone when performing PRP injections in tendon and muscle 
pathologies.  
Finally, because the methodological strength of the published literature is weak, we designed and 
implemented a methodologically rigorous randomized controlled trial (RCT) to compare the 
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effectiveness of PRP versus corticosteroid injections in patients with plantar fasciitis.  
Specifically, we built in methods to increase our certainty about our conclusions and reduce the 
potential for bias including increasing the sample size, randomization, blinding of patients and 
outcome assessors, stratification by symptom duration, and performing an adjusted analysis to 
control for differences in pre-intervention health status and characteristics. 
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Chapter 2 The Use of Platelet-rich Plasma in Orthopedic 
Pathologies 
 
 Abstract 
Platelet-rich plasma (PRP) is an autologous concentration of blood-derived human platelets in a 
small volume of plasma. The types of PRP vary according to the commercial preparation system 
used, the platelet concentration, or the anticoagulant or activator used. Autologous conditioned 
plasma is an autologous concentration of human platelets in plasma 2 to 4 times greater than that 
which is found in blood at baseline. Platelets are important to the normal healing response of 
tissue by the local secretion of growth factors and recruitment of reparative cells in an area of 
injury. PRP is theorized to create an optimal healing environment in a region of tissue injury. 
This was a literature review of currently published studies using PRP in orthopedic pathologies. 
We performed a literature search in PubMed and Medline in April 2013. We concluded that 
given the number of variations of PRP available and the lack of high-level published studies, 
there was insufficient evidence to conclusively support its clinical use.  
Key Words: autologous conditioned plasma, platelet-rich plasma, orthopedic pathologies, sports  
medicine, growth factors, tissue healing. 
 Introduction 
Platelet-rich plasma (PRP) is an autologous concentration of blood-derived human platelets in a 
small volume of plasma. Platelets are recognized as the major sources of growth factors and 
proteins associated with tissue healing within blood clots and are involved in tissue regeneration 
through the recruitment, proliferation, and differentiation of cells. The theoretical concept that 
concentrating platelets at the injured site could accelerate and optimize the healing mechanisms 
set the rationale for the development and continued research into the use of PRP in the clinical 
application for orthopedic pathologies. PRP is a general term for this type of solution and 
includes autologous conditioned plasma, platelet-enriched plasma, platelet-rich concentrate, 
autogenous platelet gel, platelet releasate, platelet rich in growth factors, and others1–3. These 
vary depending on the commercial preparation system, the platelet concentration, the 
anticoagulant or activator used, or whether the resultant PRP contains leukocytes4,5. The most 
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commonly used term in the literature is PRP. For this reason (and for simplicity) we will use the 
term PRP throughout this review to refer to the general category of solutions that result in an 
elevated concentration of platelets within a sample of plasma. 
 What are Platelets? 
Platelets are a type of white blood cell derived from the fragmentation of precursor 
megakarocytes and formed in the marrow3,6,7. They are the smallest of the blood cells, measuring 
approximately 2 µm in diameter. Platelets contain more than 30 bioactive proteins including 
some of the key growth factors, many of which have a fundamental role in the early stages of 
tissue healing3,4. Commonly found elements which are crucial to the role of tissue healing 
include platelet-derived growth factor AB, transforming growth factor b-1, and vascular 
endothelial growth factor. Plasma is the fluid content of blood and contains clotting factors and 
other proteins and ions8. The effect of PRP on tissue healing is a function of many variables, 
including platelet concentration, the volume of PRP delivered, the extent and type of pathology, 
and the overall medical condition of the patient4,9,10. Debate continues regarding the optimal 
quantity of platelets and growth factors required for soft tissue and bone healing11-16. A 
concentration 4 or more times that of whole blood has also been proposed11 but lower 
concentrations of 2 to 3 times that of baseline blood has also been shown to be effective in cell 
culture studies 12,13. Since the 1990s, PRP has been used in an array of fields including maxilla-
facial surgery11,14 and plastic surgery15,16. A growing body of laboratory evidence supports the 
use of PRP injections for the treatment of muscle and tendon pathologies and degeneration17–20. 
In vitro and in vivo studies suggest that growth factors released by platelets recruit reparative 
cells and may augment soft-tissue repair20,21. Another advantage of platelet-rich therapies is the 
antibactericidal effects of the antibacterial and fungicidal proteins stored in platelets, which may 
help to prevent infection22,23. 
 Preparation and Delivery of PRP 
There is considerable variation in the preparation of PRP. However, most processes include 
taking a sample of autologous blood and adding a form of citrate as an anticoagulant which is 
added before centrifugation of the blood6. The anticoagulants most commonly used are 
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anticoagulant citrate dextrose-A and citrate phosphate dextrose. These anticoagulants support the 
metabolic needs of platelets and the viable separation of platelets in an undamaged manner3,24,25. 
Some systems do not require the use of an anticoagulant especially if the PRP is administered 
before clotting has been initiated26. The autologous blood is spun using a centrifuge, filter, or 
separation system to separate the red blood cells from the leukocytes and platelets27. The 
resultant is a visibly layered solution of red blood cells on the bottom, a thin milky-white layer of 
leukocytes in the middle, and a yellow-tinged upper portion of PRP. The efficiency of red blood 
cell separation and platelet concentration is dependent on the preparation system used, but all 
PRP preparations contain the non-cellular components of plasma, including clotting factors27. 
PRP can be administered with or without an activating agent, such as bovine thrombin, at the 
time of delivery into the area of injury28. Both leukocyte-poor and leukocyte-rich preparations 
have been used29–31. 
 Review of the Literature 
Animal studies have been used to show the effectiveness of PRP on soft-tissue and bone healing 
as the physiology is generally known to be comparative with that of humans20,32–35. In the clinical 
setting however, results are often not as readily transferable possibly because the physical 
structure or more specifically the biomechanics and or load dispersion through soft tissues, 
joints, and bone differs between humans and animals. We conducted a search using PubMed and 
Medline in April 2013 with combinations of the following key words: platelet rich plasma, 
platelet-rich plasma, growth factors, orthopaedic pathologies, sports medicine, muscle, tendon, 
bone, and ligament. Studies were eligible for review if they explored the effectiveness of PRP in 
muscle, tendon, bone, or ligaments in humans. We further reduced this volume of literature by 
selecting those studies with the highest levels of evidence36. Each relevant study is presented in 
brief summary showing all significant findings for consideration of implications of PRP in 
orthopedic pathologies. Study details are summarized in Tables 1 and 2. 
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Study Study 
Design 
Control 
Groups 
Blinded Sample size Outcome Measures Validated 
Outcome 
measures 
Length of 
Follow-up 
(months) 
Everts et al 
(2008) 
RCT Yes Yes 
(Patients, 
Assessor) 
40 (20/20) VAS, ASES, SIS, ROM Yes 3 
Randelli et al. 
(2008) 
RCT Yes Yes 
(Patients, 
Assessor) 
53 (26/27) Constant score, VAS, SER, 
UCLA, SST, MRI, 
Ultrasound 
Yes 24 
Devos et al. 
(2010) 
RCT Yes Yes 
(Patients, 
Assessor) 
54 (27/27) VISA-A, return to sports, 
patient satisfaction, 
Yes 6 
Creaney et al. 
(2011) 
RCT Yes Yes 
(Patients, 
Assessor) 
150 (80/70) PRTEE Yes 6 
Castricini et 
al. (2011) 
RCT Yes Yes 
(Patients) 
80 (43/45) Constant score, MRI Yes (+/-) 20.2 
Gosens et al. 
(2011) 
RCT Yes Yes 
(Patients, 
Assessor) 
100 (51/49) VAS, DASH Yes 24 
Cervellin et 
al. (2012) 
RCT Yes Yes (Patient) 40 (20/20) VAS, VISA, MRI Yes 12 
Rha et al. 
(2012) 
RCT Yes Yes (Patient, 
Assessor) 
39 (20/19) SPADI Yes 6 
Weber et al. 
(2012) 
RCT Yes Yes (Patient, 
Assessor) 
60 (30/30) ROM, UCLA, SST, ASES, 
MRI 
Yes 12 
Krogh et al. 
(2013) 
RCT Yes Yes (Patient, 
Assessor) 
60 (20/20/20) PRTEE, Ultrasound Yes 12 
Klaasen et al. 
(2011) 
Retrospective 
Cohort 
Yes No 161 (76/91) Radiographs (Brooker 
Grading) 
Yes 12 
10 
 
 
 
 
Abbreviations: RCT, randomized controlled trial; ASES, American Should and Elbow Surgeons; SIS, Shoulder Index Score; VAS, 
visual analog scale; SER, strength in external rotation; SST, simple shoulder test; UCLA, University of California; VISA-A, Victorian 
Institute of Sports Assessment – Achilles; DASH, Disabilities of the Arm, Shoulder, and Hand; PRTEE, Patient-Related Tennis Elbow 
Evaluation; NPRS, Nirschl Phase Rating Scale; IKDC, International Knee Documentation Committee score; WOMAC, Western 
Ontario and McMaster Universities Arthritis Index questionnaire; AOFAS, American Orthopaedic Foot and Ankle Society; SPADI, 
Shoulder Pain And Disability Index; MRI, Magnetic Resonance Imaging  
Wei et al. 
(2012) 
Prospective 
cohort 
Yes Yes (Patient, 
Assessor) 
254 
(85/101/90) 
AOFAS, Radiographs, CT 
Scan 
Yes 72 
Wright-
Carpenter et 
al. (2004) 
Pilot study Yes No 29 (18/11) Return to sport, MRI No (+/-) 17.7 
Wetzel et al. 
(2013) 
Retrospective 
Cohort 
Yes No (Not 
mentioned) 
15 (10/5) VAS, Return to work, Return 
to sport, Patient-reported 
satisfaction, NPRS 
No 4.5 
(treatment), 
2 (control) 
Orrego et al. 
(2008) 
RCT Yes Yes (Patient, 
Assessor) 
108 
(26/27/28/27) 
MRI, Lysholm Score, IKDC Yes 6 
Nin et al. 
(2009) 
RCT Yes Yes (Patient, 
Assessor) 
100 (50/50) VAS, Anterior laxity, IKDC, 
Inflammatory parameters, 
Radiographs, MRI 
Yes 24 
Patel et al. 
(2013) 
RCT Yes Yes (Patient, 
Assessor) 
78 (27/25/26) WOMAC, VAS, Patient 
satisfaction 
Yes 6 
Table 1 Summary of Studies 
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  Study Study Design No. Of 
Studies 
Included study designs 
Sheth et al. (2012) Systematic Review 
and Meta-analysis 
33 RCT (n = 23), Prospective cohort (n = 
10) 
Chahal et al. 
(2012) 
Systematic Review 
and Meta-analysis 
5 RCT (n = 2), Prospective cohort (n = 3) 
Table 2 Systematic Reviews and Meta-analyses 
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 PRP in Tendon Healing 
Everts et al37 published results of a randomized controlled trial (RCT) that evaluated the use of 
platelet-leukocyte gel (PLG) in open subacromial decompression surgery for 40 patients  
(treatment=20, control=20) with chronic impingement syndrome of the shoulder. At 6 weeks the 
PLG group showed significant improvement in visual analog scale (VAS) pain scores that were 
part of the American Shoulder and Elbow Surgeons tool (P<0.05). Patients with PLG also used 
significantly less pain medication (P<0.05) and scored significantly better on the shoulder index 
score postoperatively (P<0.05). Patients with PLG had significantly improved scores on the 
activities of daily living questionnaire 2 weeks postoperatively (P<0.05) and demonstrated 
greater range of motion (ROM) improvement at 2 weeks (P<0.05). 
Randelli et al38 published results of a RCT for the effectiveness of PRP in tendon healing in 
patients undergoing arthroscopic repair of a complete rotator cuff tear. Patients received either an 
intraoperative application of PRP with an autologous thrombin component (n=26) or no 
treatment in the control group (n=27), and were followed up for over 2 years. Outcome measures 
were VAS for pain, Constant score, strength in external rotation (SER), Simple Shoulder Test 
(SST), University of California-Los Angeles (UCLA), and tendon integrity assessed using 
magnetic resonance imaging (MRI). The pain score in the treatment group was lower than the 
control group at 3, 7, 14, and 30 days after surgery (P<0.05). Scores on the SST, UCLA, 
Constant scores, and SER were significantly better in the treatment group than the control group 
at 3 months after surgery (P<0.05). There was no difference between the groups at 6, 12, and 24 
months. The follow-up MRI showed no significant difference in the healing rate of the rotator 
cuff tear. In the subgroup of grade 1 and 2 tears, with less retraction, SER in the PRP group was 
significantly higher at 3, 6, 12, and 24 months postoperative (P<0.05).  
De Vos et al39 performed a RCT of 54 patients with chronic Achilles tendinopathy. Patients were 
randomized to receive a PRP injection (n=27) or placebo (n=27). The validated Victorian 
Institute of Sports Assessment-Achilles (VISA-A) questionnaire, which evaluated pain score and 
activity level, was completed at baseline and 6, 12, and 24 weeks. Secondary outcomes included 
subjective patient satisfaction, return to sports, and adherence to eccentric exercises. Authors 
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found no statistically significant differences between treatment groups for any of their outcomes 
(P>0.05). 
Creaney et al40 conducted a RCT comparing autologous blood injection (n=70) and PRP (n=80) 
in patients with elbow tendinopathy who had failed conservative physical therapy. Each patient 
received 2 injections: 1 at baseline and 1 a month later. Patient-related tennis elbow evaluation 
was the primary outcome measure which patients completed at baseline, 1, 3, and 6 months. 
Authors found no statistically significant differences in the improvement of scores between 
groups (P<0.05). 
Castricini et al41 completed a RCT that included 88 patients with a rotator cuff tear who received 
arthroscopic rotator cuff repair with (n=43) or without (n=45) augmentation with autologous 
platelet-rich fibrin matrix. The primary outcome was the postoperative difference in the Constant 
score between the 2 groups, and the secondary outcome was the integrity of the repaired rotator 
cuff, as evaluated by MRI. The authors found no statistically significant differences between 
groups for either of the outcome measures (P<0.05). 
Gosens et al42 published the 2-year results for an ongoing study comparing PRP and 
corticosteroid injection for the treatment of chronic lateral epicondylitis. One hundred patients 
were randomized to a leukocyte-enriched PRP group (n=51) or the corticosteroid group (n=49). 
The primary outcomes were the pain VAS scores and the DASH outcome scores. The PRP group 
had a statistically significant reduction of 25% on pain and DASH scores (P<0.05) without a 
reintervention after 2 years. When baseline pain and DASH scores were compared with the 
scores at 2-year follow-up, both groups significantly improved across time (intention-to-treat 
principle). However, the DASH scores of the corticosteroid group returned to baseline levels, 
whereas those of the PRP group significantly improved (as-treated principle; P<0.05). 
In a RCT, Cervellin et al43 evaluated the effectiveness of PRP in 40 young athletes following 
bone-patellar tendon-bone technique for anterior cruciate ligament (ACL) pathologies. Patients 
were randomized to undergo ACL reconstruction with patellar tendon grafts and bone-patellar 
tendon-bone technique with (n=20) or without (n=20) PRP gel applied to the donor site. 
Outcome measures included reduction in anterior knee pain, kneeling pain, and donor-site 
morbidity as evidenced by evaluation of VISA and VAS scoring scales and MRI analysis of the 
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tendon and bone defect. At 12-month follow-up, VISA scores were significantly higher in the 
patients treated with PRP (P<0.05). No other outcomes were found to be statistically different. 
Rha et al44 compared the effects of 2 PRP injections (n=20) with those of 2 dry needling 
injections (n=19) in patients with a supraspinatus tendon lesion (tendinosis or a partial tear 
<1cm). The outcomes included the Shoulder Pain and Disability Index, passive ROM, a 
physician global rating scale at the 6-month follow-up, and an ultrasound measurement. There 
was a statistically significant improvement in clinical outcomes in the PRP group (P<0.05) from 
6 weeks to 6 months. At 6 months the mean Shoulder Pain and Disability Index also showed a 
statistically significant difference between groups in favor of the PRP treatment (P<0.05). 
Weber et al45 conducted a RCT to compare the effectiveness of platelet-rich fibrin matrix (n=30) 
to a control group with no injection (n=30), in the treatment of arthroscopic rotator cuff repair. 
Outcome measures collected over 1 year included pain VAS, ROM, UCLA, and SST scores, and 
recorded narcotic consumption. Mean UCLA shoulder scores were significantly better for the 
PRP group at 1 year (P<0.05). There were no statistically significant differences found for the 
other outcomes. 
Krogh et al46 compared a single injection of PRP (n=20) to a glucocorticoid injection (n=20) and 
a placebo (saline; n=20) in a RCT for patients with chronic lateral elbow epicondylitis. The 
primary outcome was reduction in pain after 3 months using the PRETEE questionnaire, and 
secondary outcomes were ultrasonographic changes in tendon thickness and color Doppler 
activity. Glucocorticoid reduced pain more effectively than did both saline and PRP at 1 month 
(P<0.05). Glucocorticoid also showed statistically significant reduction of color Doppler activity 
and reduced tendon thickness (P<0.05) compared with both PRP and saline. 
 PRP in Bone Healing 
Klaassen and Pietrzak47 completed a retrospective, controlled clinical study that examined the 
effect of PRP application during closure after total hip arthroplasty on heterotopic ossification. 
The PRP group consisted of 76 patients with 85 hips evaluated and the control group consisted of 
91 patients with 94 hips evaluated. The primary outcome was the unwanted presence of 
heterotopic ossification evaluated using radiographs and the Brooker classification immediate 
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postoperative, 6 weeks, 3 months, and 1 year. No significant differences were found between 
groups. 
Wei et al48 conducted a prospective cohort study to compare the effectiveness of PRP in the 
treatment of displaced intra-articular calcaneal fractures. Patients received one of 3 treatments: 
autograft alone (n=101), allograft combined with PRP (n=85), or allograft alone (n=90). 
Outcome measures included radiographic imaging and 3-dimensional computed tomography to 
assess the thalamic portion, Bohler angle, the crucial angle of Gissane, and the height, width and 
length of the calcaneum. The American Orthopedic Foot and Ankle Society ankle-hind-foot 
scoring system was used to evaluate the hindfoot function at intervals over a period of 6 years. 
There were statistically significant improvements for patients in the autograft and allograft with 
PRP treatment groups at 2 and 6 years compared with the allograft alone group (P<0.05) in 
radiographic assessments. 
 PRP in Muscle Healing 
Wright-Carpenter et al49 conducted a pilot study on the effects of autologous conditioned serum 
(n=18) compared with a control group using a combination of deproteinized dialysate from 
bovine blood and a homeopathic anti-inflammatory drug (Actovigan/Traumeel; n=11). Patients 
were professional sportsmen with a variety of lower limb muscle strains. Primary outcomes 
included time to return to sport and MRI. The autologous conditioned serum group returned to 
full sport participation statistically sooner than the control group (P<0.05). 
Wetzel et al50 compared the effectiveness of PRP in proximal hamstring pathologies in a 
retrospective cohort of patients. The authors included patients in an analysis who had failed 
traditional conservative treatment and had received a PRP injection (n=15) and compared them 
to a cohort who received no treatment (n=5). Outcomes included pretreatment and posttreatment 
VAS pain scores, Nirschl Phase Rating Scale scores, and return to sport. Both groups showed 
significant improvements from baseline scores, but there were no significant differences found 
between groups (P>0.05). 
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 Intra-articular Application of PRP 
Orrego et al51 completed a RCT to determine whether the use of platelet concentrate (PC) and 
bone plug (BP) accelerates healing in ACL reconstruction. Patients were randomized to PC 
(n=26), BP (n=28), combination of PC and BP (n=27), and a control group (n=27). Maturation of 
the graft was evaluated at the femoral tunnel using MRI maturation criteria defined by a low-
intensity signal, absence of osteoligamentous interface, and no widening of the femoral tunnel. 
Subjective and objective evaluations using the Lysholm and International Knee Documentation 
Committee scores were performed preoperatively and 6 months after surgery. The only 
significant difference was found at 6 months in the presence of low-intensity mature graft signal 
at the femoral tunnel in 78% of the BP group and in 100% of the PC group (P<0.05). Tunnel 
widening (negative result) was seen in 11% of the patients in the BP group versus 41% of the 
patients in the control group (P<0.05). 
Nin et al52 evaluated the use of platelet-derived growth factor in primary ACL reconstruction 
with bone-patellar tendon-bone allograft in a RCT of 100 patients. Patients received either 
platelet-enriched gel (n=50) or a nongel (n=50). Patients were followed at intervals for a period 
of 24 months and outcome measures were the pain VAS, anterior laxity assessed using an 
arthrometer, the International Knee Documentation Committee scores, C-reactive protein levels, 
knee circumference, MRI and radiographic measures. The results did not show any statistically 
significant differences between the groups for inflammatory parameters, MRI appearance of the 
graft, and clinical evaluation scores (P>0.05). 
Patel et al53 assessed the use of PRP in a RCT of 78 patients (156 knees) with bilateral 
osteoarthritis of the knee. Patients were divided into 3 treatment groups: group A (52 knees) 
received a single injection of PRP, group B (50 knees) received 2 injections of PRP 3 weeks 
apart, and group C (46 knees) received a single injection of normal saline. Outcome measures 
included the Western Ontario and McMaster (WOMAC) Universities Arthritis Index  
questionnaire and pain VAS. Patients were assessed at baseline, 6 weeks, 3 months, and 6 
months after treatment. Groups A and B showed significant improvements in all WOMAC 
parameters and pain VASs at all time points when compared with group C (P<0.05), but no 
difference observed when comparing groups A and B (P>0.05). 
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 Systematic Reviews 
In a systematic review and meta-analysis conducted by Sheth et al54 that included most studies 
already described, pain and improved healing and function was evaluated in patients with 
orthopedic pathologies after the use of PRP. Twenty-three randomized trials and 10 prospective 
cohort studies met the eligibility criteria. However, the authors concluded that among the 
identified studies, the PRP products utilized were too dissimilar from each other to justify 
making a broad statement about the effectiveness of all PRP products and that more studies need 
to be conducted so that future reviews could present independent analyses by PRP product. 
Chahal et al55 completed a systematic review of the literature and subsequent meta-analysis on 
the clinical efficacy of PRP in arthroscopic rotator cuff repair of patients with full-thickness 
rotator cuff tears. Five studies (2 randomized and 3 nonrandomized with comparative control 
groups) met the inclusion criteria, with a total of 261 patients. Quantitative synthesis of all 5 
studies using a random effects model showed that there was no statistically significant difference 
in the overall rate of rotator cuff retears between patients treated with PRP and those treated 
without PRP (risk ratio, 0.77; 95% confidence interval, 0.48-1.23). There were also no 
statistically significant differences in the pooled Constant score, SST, American Shoulder and 
Elbow Surgeons, UCLA, or SANE score. 
 Conclusion 
There are currently no clear indications for the use of PRP in orthopedic pathologies. There is a 
lack of homogenous, high level studies evaluating the effect of PRP in orthopedic pathologies, 
thus precluding attempts to pool results across studies and preventing us from making 
conclusions with any degree of certainty. 
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Chapter 3 Ultrasound versus palpation guided PRP injections in 
tendon and muscle pathologies: A systematic review and meta-
analysis of randomized and non-randomized trials 
 Abstract 
Background: There is controversy as to whether the effectiveness of platelet rich plasma (PRP) 
injections for non-operative treatment of muscle and tendon pathologies is affected by the 
method of administration. Compared to palpation alone, ultrasound guided injections may offer 
improved accuracy and subsequent greater effectiveness of PRP for tendon and muscle 
pathologies. 
Objectives: The purpose of this systematic review and meta-analysis was to evaluate the 
effectiveness of ultrasound guided versus palpation guided PRP injections for the treatment of 
tendon and muscle pathologies. 
Search methods: We searched Pubmed, Medline Ovid, CINAHL, Scopus, SportDiscus, 
EMBASE, and Cochrane Library from inception to December 2014. We also searched references 
of recently published review papers and systematic reviews.  
Selection criteria: We included Level I, II, and III comparative studies evaluating PRP injection 
versus a non-PRP control for the non-operative treatment of muscle and/or tendon injury.  
Data collection and analysis: Two independent reviewers assessed the titles and abstracts of 
5178 studies. Seventy-one studies were identified for full text review, and 26 studies were 
included in the final analysis. We used a modified version of the Cochrane Collaboration tool to 
assess risk of bias of included studies. We included 18 studies in our meta-analysis. There were 
no studies directly comparing ultrasound versus palpation guided injections of PRP, thus we used 
an indirect comparison using random-effects with associated P values and 95% confidence 
intervals (CI). We assessed heterogeneity of studies using an I2 and Tau2 statistic and Chi2 test. 
Specifically, we expected larger effects in studies sponsored by an interested party versus not, 
and in those studies with a high risk of bias versus not. We also thought heterogeneity may be 
explained by creating subgroups and therefore explored whether heterogeneity was decreased if 
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we separated studies that evaluated outcomes in tendon versus muscle, acute (<3 months 
symptom duration) versus chronic (>3 months symptom duration) pathologies, active control 
versus sham or placebo, platelet concentration (≤3 versus >3 times baseline blood),and intra-
articular injection versus not.  
Main results: We found no statistically significant difference in failure rates between patients 
whose PRP injection was ultrasound-guided or not. There was also no significant difference in 
pain at less than two months, two to three months, and six months following PRP injection. 
Disability and functional outcomes at six months had high heterogeneity which could not be 
explained by our a priori expectations. Therefore, we were unable to make any definitive 
conclusions about the difference in disability and functional outcomes between ultrasound versus 
palpation guided injections.  
Conclusion: There is no evidence to date that ultrasound-guided injection of PRP offers better 
outcomes than palpation alone.  
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 Introduction 
Over the past decade, the body of literature evaluating the effectiveness of platelet rich plasma 
(PRP) for the treatment of musculoskeletal pathologies has increased. Its purported regenerative 
properties drive its continued use as a treatment for tendon, muscle, bone and cartilage, while the 
autologous nature of PRP and relative ease of preparation, and contribute to its appeal. 
Platelets are discoid cells that contain over 30 bioactive proteins in the form of growth factors1. 
At the time of injury, platelets are activated in the presence of damaged tissue and aggregate 
together to release the growth factors which stimulate the inflammatory response and initial 
healing process2. PRP is a concentrated solution of blood platelets suspended in plasma. By 
injecting PRP in the injured area, the localized concentration of these growth factors may 
accelerate tissue and wound healing3,4.  
PRP is obtained from the venous blood of the patient. The process of centrifugation separates the 
blood into a distinctly layered solution of red blood cells and concentrated platelets in plasma. 
The PRP is then extracted and injected into the area of injury. Variability in the process depends 
on the system used and may include variations in time and speed of centrifugation, as well as the 
addition of an anticoagulant prior to centrifugation and/or an activator shortly before the 
injection5.  
A number of studies have investigated the effectiveness of PRP injections for the non-operative 
treatment of tendon pathologies6–9, and a limited few in muscle pathologies10–12. The results, 
however, remain inconclusive with a continued need for higher powered randomized controlled 
trials with standardized procedures including preparation methods, administration techniques, 
and evaluation of outcomes13,14,15.  
One area of considerable debate is whether patient outcomes are more favourable when 
clinicians use ultrasound to guide the placement of the injection versus relying on palpation 
alone. Critics argue that neglecting to use ultrasound to guide PRP injections may decrease the 
accuracy of the placement of the solution, in turn decreasing the effectiveness of PRP16,17.  
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Hall et al.18 defined accuracy of an injection treatment as the placement of the needle tip in the 
target area of the joint or tissue. The accuracy of an injection may be highly dependent on the 
target structure (i.e. joint, tendon, or muscle) and expertise of the clinician. Specifically, injured 
tendon and muscle structures are easier to locate via palpation compared to intra-articular 
structures. The gap in an Achilles tendon rupture, for example, is easier to locate via palpation 
than an intra-articular injection for rotator cuff tendinosis. For this reason, most published studies 
evaluating the effectiveness of ultrasound guided versus palpation guided injections have 
focused on intra-articular pathologies, and less on tendon, with even fewer focusing on muscle.  
For example, in 80 cadavers, Patel et al (2012)19 compared the effectiveness of ultrasound guided 
versus palpation guided injections in the glenohumeral joint and found significantly greater 
accuracy for the ultrasound guided approach (92.5%) over the palpation guided injections 
(72.5%). Similarly, Peck et al (2010)20 compared the accuracy of ultrasound (n=10) versus 
palpation (n=10) guided injections in the acromioclavicular joint of unembalmed cadavers and 
found significantly greater accuracy in the ultrasound (100%) compared to the palpation guided 
application (40%) (p < 0.05).  
Conversely, in living humans with complaints about an intra-articular structure, Rutten et al.21 
reported 100% accuracy for both ultrasound (n = 10) and palpation guided (n = 10) injections of 
the subacromial-subdeltoid bursa in a RCT of patients with shoulder impingement syndrome (p > 
0.05). In a study  evaluating shoulder pain following intra-articular injection for soft tissue and 
joint pathologies of the shoulder, Uncuncu et al.22 found a significant improvement (p < 0.05) in 
the VAS pain scores and Constant scores in patients who received ultrasound guided injections 
(n = 30) versus anatomical landmark-guided injections (n = 30) of corticosteroids. Similarly, in a 
RCT by Zufferey et al.23, the authors found a statistically significant improvement (p < 0.05) in 
pain at rest and percentage of good responders (defined as greater than 50% reduction in pain) at 
two and six weeks follow up in patients who received ultrasound guided (n = 27) versus those 
who received palpation guided (n = 29) injections of corticosteroids for the treatment of shoulder 
pain. Naredo et al.24 also found a statistically significant improvement (p < 0.05) of VAS pain 
scores and shoulder function assessment (SFA) scores at six weeks, in patients randomized to 
receive ultrasound guided injections (n = 21) versus  palpation guided injections (n = 20) of 
corticosteroids for painful shoulder pathology.   
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Conversely, Hashiuchi et al.25 published the results of a randomized controlled trial comparing 
the accuracy of ultrasound (n=15) versus palpation guided injections (n=15) of the biceps tendon 
sheath (tendon versus intra-articular pathology), a palpable tendon. A blinded assessor judged the 
presence of a contrast agent within the tendon sheath using a CT scan and found that the 
ultrasound guided injections had significantly greater accuracy (86.7% versus 26.7%) in the 
injection reaching the target area within the tendon sheath (p < 0.05). Regarding patient 
outcomes, in 2011, Zhang et al.26 found a statistically significant improvement of VAS pain 
scores and Constant-Murley scores (p < 0.05) for ultrasound guided injections in patients with 
biceps brachii tendinitis at an average follow up of 31 weeks in a RCT comparing ultrasound (n 
= 53) versus palpation (n = 45) guided corticosteroid injections.  
Li et al. 27 published a systematic review in 2014 comparing the effectiveness of ultrasound 
versus palpation guided corticosteroid injections in 149 patients with plantar fasciitis. The 
authors found a statistically significant greater improvement in the ultrasound-guided group for 
tenderness threshold, plantar fascia thickness, and hypoechogenicity (p < 0.05). However, there 
was no significant difference between treatments for VAS pain, Heel Tenderness Index (HTI), 
and response rate defined as complete relief of symptoms after one injection (p > 0.05).  In 
summary, ultrasound guided injections may be more accurate especially for intra-articular 
injections, but whether or not this translates to better outcomes seems more likely for intra-
articular pathology than tendon or muscle pathology.  
To date, there are no published studies directly comparing ultrasound versus palpation guided 
injections for PRP in musculoskeletal pathologies. Therefore, we conducted a systematic review 
and meta-analysis to evaluate the effectiveness of ultrasound versus palpation guided injections 
of PRP to reduce pain and improve function for patients with tendon and muscle pathologies.  
 Methods 
 Protocol 
We followed the PRISMA guidelines for reporting a systematic review and meta-analysis28. 
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 Eligibility Criteria 
We included studies that compared the effectiveness of PRP injections versus a non-PRP control 
group. Inclusion criteria consisted of human studies evaluating treatment of muscle and/or 
tendon pathologies using a non-surgical approach, with an evidence level of I, II, or III 
comparative design. We excluded animal, cadaveric, and lab studies; and studies evaluating 
bone, ligament, cartilage, and wound care pathologies.  
 Information sources and searches 
We consulted with a university librarian to aid with our search of Pubmed, Medline Ovid, 
CINAHL, Scopus, SportDiscus, EMBASE, and Cochrane Library from inception to December 
2014 (Appendix 3). We also searched the references of recently published reviews and 
systematic reviews evaluating the effectiveness of PRP in musculoskeletal pathologies29–34. Our 
keyword search included “muscle or tendon” combined with variations of the terms “platelet rich 
plasma” and “injection”.  
 Study Selection 
Two reviewers (N.K. and L.C.) independently read the titles and abstracts to determine study 
eligibility. We reviewed the full text of any study classified by either reviewer as eligible or 
uncertain. The same independent reviewers screened the full text articles using the same 
eligibility criteria. Any disagreement was resolved by an independent third party (A.R.). We 
completed an inter-rater agreement assessment for categorical data for the full text review using 
a Kappa statistic. 
 Data collection process  
Two reviewers (N.K. and A.R.) independently extracted data from eligible studies. 
Disagreements between reviewers were resolved by discussion and remaining disagreements 
were adjudicated by an arbitrator (D.B.). 
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 Data items 
We extracted patient population information, treatment and control used, and outcome measures. 
Additionally, we included details of the diagnosis, symptom duration, and the addition of 
anticoagulants and/or activators to the injection procedure. We contacted the authors of seven 
studies to obtain additional information or data. We received additional data from five authors35–
38, and no response from two authors of three studies39–41. 
 Risk of bias in individual studies 
Two independent reviewers (N.K. and L.C.) assessed the risk of bias for each study using a 
modified version of the Cochrane Collaboration’s tool for assessing risk of bias in randomized 
trials42. Disagreements between reviewers were resolved by discussion and remaining issues 
were adjudicated by one of two arbitrators (A.R. and D.B.).We rated the domains for each study 
as “high risk” of bias, “low risk” of bias, or “unclear risk”. A study was classified as “high risk” 
if the particular criteria that posed a threat to the internal validity was not adequately prevented. 
A “low risk” of bias meant that the study took all possible precautions to protect the internal 
validity. We labelled the study as having an “unclear risk” of bias when there was limited 
information from which to assess bias. Risk of bias guidelines are described in Table 3. 
Risk of bias guidelines 
RCT's 
Domain Description 
Sequence 
generation 
Judged on the likelihood of the method to generate a randomization 
sequence (e.g. random computer generated (“low”) versus odd or even date 
of birth (“high”)) that will result in balanced treatment groups  
Allocation 
concealment 
Judged on the effectiveness of the study protocol to reduce the 
predictability of group allocation (e.g. open list (“high”) versus 
sequentially numbered, opaque, sealed envelopes (“moderate”) versus list 
of managed independently or by computer with checks for duplicate or 
withdrawn patients (“low”). 
Blinding Judged on the ability of the protocol to blind the patient, caregiver, and/or 
outcomes assessor where possible, so as not to influence the outcomes  
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Attrition Judged on how likely missing data was related to the treatment or outcome; 
the balance of missing data between treatment groups; and how likely 
missing data would influence the results (tolerance). 
Reporting Judged on the study results being reported as specified in the study 
protocol (i.e. all primary and secondary outcomes were reported using the 
pre-specified measurements and analyses of all data in its entirety). 
Other Judged on the presence of the occurrence of another factor that may have 
influenced the study results (e.g. study stopped early or fraudulent claims). 
Cohort studies 
Domain Description 
Selection bias Judged on the population sampling method and the unbiased allocation of 
participants to the treatment groups. 
Balance of 
prognostic 
factors 
Determined by the balance of participant baseline characteristics between 
treatment groups. 
Unbiased 
outcome 
assessment 
Judged on the ability of the protocol to blind the patient, caregiver, and/or 
outcomes assessor where possible, so as not to influence the outcomes  
Attrition Judged on how likely missing data was related to the treatment or outcome; 
the balance of missing data between treatment groups; and how likely 
missing data would influence the results (tolerance). 
Reporting Judged on the study results being reported as specified in the study 
protocol (i.e. all primary and secondary outcomes were reported using the 
pre-specified measurements and analyses of all data in its entirety).  
Other Judged on the presence of the occurrence of another factor that may have 
influenced the study results (e.g. study stopped early or fraudulent claims). 
Table 3 Risk of bias assessment tool used for RCT’s and Cohort studies 
 Summary measures 
We analysed pooled data using standard meta-analysis methods with Review Manager (version 
5.3)43. We consulted with an orthopaedic surgeon (K.W.) to establish common follow up times 
and outcome measures amongst the studies. We calculated differences between treatment groups 
using odds ratios with 95% CI for dichotomous data. For continuous data we used standardized 
mean differences (SMD) with 95% CI for comparisons measuring the same outcome using 
different scales44 (Cochrane handbook).  
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 Synthesis of results 
We extracted data from studies to compare failure rates as defined by the individual study. If 
more than one time point was provided in studies, we used the final follow up scores in the 
analysis. For the continuous outcome measure (pain and patient-reported disability and function) 
we conducted two analyses at each follow up time point; a change score (final outcome – 
baseline) and a raw score (final outcome only).   For analyses evaluating a pain VAS some 
studies reported a score from a 10 cm line ranging from 0-10 while others reported a score from 
0-100. We converted scores on a scale of 0-100 to a standardized scale of 0-10 prior to pooling 
the results. We extracted scores of VAS pain scales at three different time intervals: 1) less than 
two months, 2) two to three months, and 3) six months post-injection.  
We compared change in disability and functional outcome scores for ultrasound versus palpation 
studies at six months follow up. We standardized scores to a scale where a lower score represents 
worse ability or function.  
If not already provided, we converted scores for each study to a mean and standard deviation of 
the change in score from baseline. When a mean and range were provided, we calculated an 
estimated standard deviation as follows: 
   (upper limit – lower limit)/4 
When a mean and confidence intervals were provided, we calculated the standard deviation as 
follows (Cochrane handbook 7.7.3.2). 
SD = √𝑛 x (Upper limit – Lower limit)/3.92 
We found no studies that directly compared ultrasound guided PRP injections versus palpation 
guided PRP injections. For this reason we completed an indirect comparison of treatment effects 
as suggested by Bucher et al.45. For each follow up period of each outcome measure, we 
completed subgroup analyses comparing (1) ultrasound guided PRP injections versus control 
groups; and (2) palpation guided PRP injections versus control groups. We completed a 
comparison of subgroups in RevMan 5.3 which calculated the between subgroup differences 
with an associated Chi2, degrees of freedom, p value, and measure of heterogeneity (I2). This test 
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takes into consideration the overlap of confidence intervals of the summary estimates in the two 
subgroups. If the confidence intervals overlap, there is no difference between the treatments. If 
the confidence intervals do not crossover, there is a significant difference in effect of treatment.  
We did not perform analyses if there were less than two studies in a subgroup comparison. We 
used inverse variance and a random-effects approach for our meta-analyses. We assessed 
heterogeneity using a Chi2 test and I2 and Tau2 statistic46, where an I2 greater than or equal to 
60% was considered the maximum threshold for total heterogeneity44. For any comparison with 
heterogeneity greater than the threshold, we performed additional heterogeneity analyses guided 
by our a priori hypotheses. Specifically, we expected larger effects in studies sponsored by an 
interested party versus not, and in those studies with a high risk of bias versus not. We also 
hypothesized that heterogeneity may be explained by creating subgroups and therefore explored 
whether heterogeneity was decreased if we separated studies that evaluated outcomes in tendon 
versus muscle, acute (<3 months symptom duration) versus chronic (>3 months symptom 
duration) pathologies, active control versus sham or placebo, platelet concentration (≤3 versus >3 
times baseline blood), and intrarticular versus palpable structures. 
 Results 
 Study selection 
Our search yielded 8601 studies (Fig. 1). We identified ten additional studies from the reference 
lists of review papers. After removal of duplicates, 5179 titles and abstracts remained; 5108 
studies were excluded and 71 studies underwent full text review. Following full text review, 26 
studies were determined eligible. Inter-rater agreement was excellent (κ=0.88). 
 Study characteristics 
Table 4 and Table 5 describe the included studies. Fourteen studies used ultrasound guided 
injections during PRP administration, and 12 used palpation alone. Eighteen of the included 
studies were randomized controlled trials, four were prospective comparative studies and four 
were retrospective comparative studies.  
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# of records removed for 
duplication (n = 3432) 
# of records identified through 
database searching (n = 8601) 
# of additional records identified 
through other sources (n = 10) 
# of full text articles 
excluded, with reasons 
 
n=18 Conference abstracts 
n=10 Review, Editorial, 
Commentary papers 
n=5 Case series 
n=3 Protocol papers 
n=2 Animal studies 
n=2 Surgical interventions 
n=1 Compares PRP to PRP 
n=1 Exam paper 
# of records screened for titles 
and abstracts (n = 5179)  
# of records screened for full 
text review (n = 71) 
# of records excluded 
through titles and abstract 
screening (n = 5108) 
# of articles included in 
quantitative synthesis (meta-
analysis) (n = 18) 
# of articles included in 
qualitative synthesis (n = 
26) (excluding 3 duplicate 
publications) 
Figure 1 Flow diagram of search process of studies 
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Study Design Pathology ¶PRP treatment 
(Preparation 
System and 
other) 
Control N size Outcomes Follow 
ups 
Additives Results 
de Vos 
201047/ de 
Jonge 
201138/ de 
Vos 
201115 
RCT Achilles 
tendionpathy 
RecoverTM Kit, 
Biomet 
Saline 27/27 VISA-A, Patient 
satisfaction, Return 
to Sports, 
Adherence to 
eccentric exercise, 
Ultrasound 
measures 
6 wks; 3, 
6 mos; 1 
yr 
Citrate No 
differen
ce 
Creaney 
201136 
RCT Elbow 
tendinopathy 
Unspecified Autologous 
blood 
80/70 PRTEE 1, 3, 6 
mos 
Citrate 
anticoagul
ation 
Favour
ed 
control 
Thanasas 
201148 
RCT Chronic 
Lateral 
Epicondylitis 
RecoverTM Kit, 
Biomet 
Autologous 
blood 
14/14 VAS pain, 
Liverpool elbow 
score 
6 wks; 3, 
6 mos 
Anticoagu
lant 
(unspecifi
ed) 
No 
differen
ce 
Rha 
201249 
RCT Rotator cuff 
(tendinosis or 
partial tear) 
Prosys PRP Kit Dry needling 20/19 SPADI, ROM, 
Adverse effects, 
Ultrasound 
3, 6 mos ACD-A Favour
ed PRP 
Bubnov 
201337 
RCT Muscle injury Unspecified and 
Conservative 
therapy 
Conservative 
therapy 
15/15 VAS pain, 
Strength, ROM, 
Resistance 
assessment, Global 
function score 
1, 7, 14, 
21 days; 
1 mos 
Trisodium 
citrate 
buffer  
No 
differen
ce 
Chew 
201350 
RCT Plantar 
fasciitis 
ACP® Double 
Syringe, Arthrex 
and 
Conservative 
1) 
Extracorpore
al shock 
wave therapy 
and 
Conservative; 
2) 
19/19/16 VAS pain, AOFAS 
ankle-hindfoot 
scale 
1, 3, 6 
mos 
None No 
differen
ce 
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Conservative 
alone 
Kesikbur
un 201335 
RCT Chronic rotator 
cuff 
tendinopathy 
Recover Kit, 
Biomet (GPS III 
System) 
Saline 20/20 WORC, SPADI, 
VAS pain with 
Neer Impingement 
Sign, ROM 
3, 6 wks; 
3, 6 mos; 
1 yr 
None No 
differen
ce 
Krogh 
201340 
RCT Lateral 
Epicondylitis 
Recover Kit, 
Biomet (GPS III 
System) 
1) Saline;2) 
Glucocorticoi
d 
20/20/20 PRTEE, Ultrsound 
measures, pain 
score.adverse 
events 
1, 3, 6 
mos; 1 yr 
Sodium 
citrate 
No 
differen
ce 
Rettig 
201351 
Retrospe
ctive 
comparat
ive study 
Hamstring 
pathologies 
Recover Kit, 
Biomet (GPS III 
System) and 
Physiotherapy 
Physiotherap
y 
5/5 Return to sport 6 mos ACD-A, 
sodium 
bicarbonat
e 
No 
differen
ce 
Tiwari 
201352 
RCT Plantar 
fasciitis 
Unspecified Methyl 
prednisolone 
acetate 
(steroid) 
30/30 VAS pain 1, 3, 6 
mos 
None No 
differen
ce 
Vetrano 
20136 
RCT Jumper's knee MyCells® 
Autologous 
Platelet 
Preparation 
System 
Extracorpore
al shock 
wave therapy 
23/23 VISA-P, VAS 
pain, modified 
Blazina 
2, 6, 12 
mos 
ACD-A Favour
ed PRP 
Dragoo 
201453 
RCT Patellar 
tendinopathy 
Recover Kit, 
Biomet (GPS III 
System) 
Dry needling 10/13 VISA, Tegner, 
Lysholm, VAS 
pain, SF-12 
3, 6 wks; 
2, 3, 6 
mos 
None No 
differen
ce 
Hamid 
201411 
RCT Grade 2 
Hamstring 
muscle 
pathologies 
Recover Kit, 
Biomet (GPS III 
System)and 
Physiotherapy 
Physiotherap
y 
14/14 Return to sport, 
BPI-SF pain scores 
2.5 mos None Favour
ed PRP 
Reurink 
201454 
RCT Hamstring 
pathologies 
ACP® Double 
Syringe, Arthrex 
Saline 41/39 Return to sport, 
Rate of reinjury 
2, 6 mos None No 
differen
ce 
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Table 4 Ultrasound guided study details 
RCT = randomized controlled trial, PRTEE = patient-rated tennis elbow evaluation, VISA-A = Victorian institute of sport assessment 
scale Achilles, VAS = visual analogue scale, SF-12 = short form 12, SPADI = shoulder pain and disability index, ROM = range of 
motion, ACD-A = anticoagulant citrate dextrose solution A, BPI-SF = brief pain inventory short form, WORC = Western Ontario 
rotator cuff index, wks = weeks, mos = months, yr = year. ¶See Appendix 1 for system details  
Study Design Pathology ¶PRP 
treatment 
(Preparation 
System and 
other) 
Control N size Outcomes Follow 
up 
Additives Results 
Wright-
Carpent
er 200412 
Retrospective 
comparative 
study 
Muscle 
pathologies 
(variety) 
Orthokine®, 
Autologous 
Conditioned 
Serum 
Actovegin/ 
Traumeel 
18/11 Return to 
sport, MRI 
analysis 
16 days None Favour
ed PRP 
Mishra 
200641 
Prospective 
comparative 
study 
Chronic 
elbow 
tendinosis 
Recover Kit, 
Biomet (GPS 
III System) 
Bupivacaine 
with 
epinepherine 
15/5 VAS pain, 
Modified 
Mayo score 
4wks; 
2, 6 
mos 
Sodium 
citrate + 
Sodium 
bicarbonat
e buffer 
Favour
ed PRP 
Filardo 
201055 
Prospective 
comparative 
study 
Chronic 
refractory 
patellar 
tendinopathy 
Not mentioned 
and 
Physiotherapy 
Physiotherap
y 
15/16 Tegner, EQ 
VAS, pain 
scale, 
complications, 
return to sport, 
patient 
satisfaction 
1, 6 
mos 
Calcium 
cholride 
No 
differen
ce 
Peerboo
ms 
RCT Lateral 
Epicondylitis 
Recover Kit, 
Biomet (GPS 
III System) 
Corticosteroi
ds 
51/49 VAS pain 
scale, 
Disabalities of 
1, 2, 3, 
6, 12, 
24 mos 
Sodium 
citrate + 
Sodium 
Favour
ed PRP 
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201056/ 
Gosens 
201157 
the Arm, 
Shoulder and 
Hand (DASH) 
bicarbonat
e buffer 
Aksahin 
201258 
Prospective 
comparative 
study 
Plantar 
Fasciitis 
Not mentioned Metilpredniza
lone 
30/30 VAS pain 
scale, Roles 
and Maudsley 
score 
3 wk, 
6mos 
Calcium No 
differen
ce 
Omar 
201259 
RCT Plantar 
Fasciitis & 
Tennis Elbow 
Not mentioned Corticosteroi
ds 
(15/15
)/(15/
15) 
VAS, DASH 
(elbow), FHSQ 
(foot) 
6 wks Citrate 
phosphate 
dextrose  
No 
differen
ce (TE) 
Favour
ed PRP 
(PF) 
Kearney 
201360 
RCT Achilles 
tendinopathy 
GenisisCS 
Component 
Concentrating 
System 
Eccentric 
loading 
programme 
10/10 VISA-A, EQ-
5D 
6wks; 
3, 6 
mos 
Citrate 
anticoagul
ant 
No 
differen
ce 
Wetzel 
201361 
Retrospective 
comparative 
study 
Hamstring 
pathologies 
Recover Kit, 
Biomet (GPS 
III System) 
None 10/5 VAS pain, 
Nirschl Phase 
Rating Scale 
Score, Return 
to Sport 
4.5/2 
mos 
None No 
differen
ce 
Kaniki 
20147 
Retrospective 
comparative 
study 
Achilles 
tendon 
ACP® Double 
Syringe, 
Arthrex and 
Accelerated 
Rehabilitation 
Accelerated 
Rehabilitation 
72/73 Strength, 
ROM, Calf 
circumference, 
Leppilahti 
scale, AOFAS 
(PRP only) 
6 wks; 
3, 6, 
12, 18, 
24 mos 
None No 
differen
ce 
Mishra 
201439 
RCT Tennis Elbow Recover Kit, 
Biomet (GPS 
III System) 
Bupivacaine 112/1
13 
Safety, VAS 
with resisted 
wrist 
extension, 
PRTEE, 
1, 2, 3, 
6 mos 
ACD-A + 
sodium 
bicarbonat
e 
Favour
ed PRP 
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extended wrist 
exam, success 
rate  
Raeissad
at 201462 
RCT Lateral 
Epicondylitis 
Rooyagen Kit 
Leukocyte-
enriched PRP 
Autologous 
Blood 
23/22 VAS, modified 
Mayo Clinic 
performance 
index for the 
elbow, and 
pressure pain 
threshold 
(PPT) 
4, 8 
wks 
ACD-A  Favour
ed PRP 
Say 
201463 
Prospective 
comparative 
study 
Plantar 
fasciitis 
Not mentioned Methylpredni
solone 
(steroid) 
25/25 VAS, AFAS 6wks, 6 
mos 
Sodium 
citrate + 
calcium 
chloride 
Favour
ed PRP 
Table 5 Palpation alone study details 
VAS = visual analogue scale, DASH = disabilities of the arm, shoulder and hand, MRI = magnetic resonance imaging, EQ VAS = 
Euroqol visual analogue scale, FHSQ = foot health status questionnaire, PPT = pressure pain threshold, ACD-A = anticoagulant citrate 
dextrose solution A, ROM = range of motion, AOFAS AHS = American orthopedic foot and ankle society ankle-hindfoot scale, 
AFAS = American foot and ankle score, wks = weeks, mos = months, yr = year. ¶See Appendix 1 for system details  
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 Risk of Bias within studies  
A summary of the risk of bias assessments for RCT’s and cohorts can be found in Table 6 and 
Table 7. Most of the RCT’s maintained an overall low risk of bias due to their randomized 
design which accounts for sequence generation and allocation concealment when performed 
adequately.  The majority of cohort studies had an overall risk of bias that was either low or 
unclear. The absence of randomization introduces a greater risk of selection bias. However, we 
also assessed the demographics table of the included studies to determine if known prognostic 
factors were balanced between groups and better understand the likelihood that a selection bias 
was present.  
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Creaney 2011 Unclear Low Low Low Low Low 
de Jonge/de Vos 2011 Low Low Low Low Low Low 
Gosens/Peerbooms 2011 Low Low Low Low Low Low 
Thanasas 2011 Low Low Low Low Low Low 
Omar 2012 Unclear Unclear High Low Low Low 
Rha 2012 Low Low Low Low Low Low 
Bubnov 2013 Unclear Unclear High Low Low Low 
Chew 2013 Low Low Low Low Low Low 
Kearney 2013 Low Low Low Low Low Low 
Kesikburun 2013 Low Low Low Low Low Low 
Krogh 2013 Low Low Low High High Low 
Tiwari 2013 Unclear Unclear Unclear Low Low Low 
Vetrano 2013 Low Unclear Low Low Low Low 
Dragoo 2014 Low Low Low Low High High 
Hamid 2014 Low Low Low Low Low Low 
Mishra  2014 Low Low Low High High Low 
Raeissadat 2014 Low Unclear Low Low Low Low 
Reurink 2014 Low Low Low Low Low High 
Table 6 Risk of bias assessment for RCT’s 
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Wright-
Carpenter 
2004 Unclear High Unclear Low Low Low 
Mishra 2006 Unclear High Low High High Low 
Aksahin 2010 Low Low Low Low Low Low 
Filardo 2010 High High Low Low Low Low 
Wetzel 2013 Low High Unclear Low High Low 
Rettig 2013 Unclear Low Low Low Low Low 
Kaniki 2014 Low Low High High Low Low 
Say 2014 High Low Low Low Low Low 
Table 7 Risk of bias assessment of cohort studies 
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 Summary results 
 Failure rates 
Failure rates were reported in five studies. Two studies defined failure as less than 25% 
improvement of VAS scores from baseline at six months and one year respectively. Two studies 
reported patient dissatisfaction as failure at one year, and one study defined less than 25% 
improvement of scores from baseline to six months on the PRTEE questionnaire as failure.  
We found no statistically significant differences between the treatment effects of ultrasound 
versus palpation guided studies for the comparison of failure rates (p = 0.17) (Figure 2). 
Heterogeneity of the group differences was moderately low with I2 = 46.5%. The overall 
heterogeneity of studies included in the analysis for both treatments was high (I2 = 70%).  
 
Figure 2 Comparison of failure rates in ultrasound (US) versus palpation (non-US) guided 
injections of PRP. 
 
 
44 
 
 VAS Pain scale outcomes   
Pain as measured with the visual analogue scale (VAS) was assessed in 13 of the included 
studies. One study measured pain using the BPI-SF pain scores64 which measured pain intensity 
as an average of five VAS pain scales with a total score out of 10.  Because the metric differed 
between studies, we used the standardized mean difference to pool the results. 
We found no statistically significant differences between the treatment effects of ultrasound 
versus palpation guided injections at less than two months for the change in VAS pain scores 
from baseline (p = 0.60) (Fig. 3). Heterogeneity of the group differences was low with I2 = 0%. 
In addition, we compared raw scores between treatment groups at less than two months and 
found no significant difference in treatment effect between groups (p = 0.37).    
     
Figure 3 Comparison of change in scores from baseline ultrasound (US) versus palpation 
(non-US) guided injections of PRP using the VAS pain scale outcome measure at less than 
two months follow up. 
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Despite statistically favourable outcomes for patients receiving a PRP injection (p <0.01) at two 
to three months, there was no evidence to support the use of ultrasound guidance over palpation 
alone (p = 0.62). (Fig. 4). Heterogeneity of the group differences was low with I2 = 0%. In 
addition, we compared raw scores between treatment groups at two to three months and found no 
significant difference in treatment effect between groups (p = 0.22).  
 
Figure 4 Comparison of change in scores from baseline ultrasound (US) versus palpation 
(non-US) guided injections of PRP using the VAS pain scale outcome measure at two to 
three months follow up. 
Despite statistically favourable outcomes for patients receiving a PRP injection (p=0.0001) at six 
months, there was no evidence to support the use of ultrasound guidance over palpation alone 
(p=0.47). (Fig. 5). Heterogeneity of the group differences was low with I2 = 0%. In addition, we 
compared true scores between treatment groups at six months and found no significant difference 
in treatment effect between groups (p = 0.64). 
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Figure 5 Comparison of change in scores from baseline ultrasound (US) vers of change in 
scores from baseline ultrasound (US) versus palpation (non-US) guided injections of PRP 
using the VAS pain scale outcome measure at six months follow up. 
 Disability and functional outcome scores 
The outcome measures used in the studies included the DASH, SPADI, VISA-A, VISA-P, 
PRTEE, AFAS, and Liverpool Elbow Scale1. Because the metric differed between studies, we 
used the standardized mean difference to pool the results. One of the studies included both the 
SPADI questionnaire, and the Western Ontario Rotator Cuff index (WORC) as outcome 
measures. We chose to use the data of the SPADI in our analysis as it was a region-specific 
                                                 

 The DASH is a self-reported, region-specific, 30-item instrument that measures upper-extremity disability and 
symptoms on a scale of zero to 100 (0 = no disability). The SPADI is a self-reported, region-specific outcome that 
measures current shoulder pain and disability. The VISA-A is a self-reported, region-specific outcome that measures 
pain, function in daily living, and sporting activity in Achilles tendon pathology. The VISA-P measures a similar 
construct to the VASA-A but is specific to the patella tendon. The PRTEE is a 15-item questionnaire that measures 
forearm pain and disability in patients with lateral epicondylitis. The AFAS is a region-specific questionnaire of the 
foot and ankle that consists of nine items scored on a scale of 100 (100 = no disability). The Liverpool Elbow Scale 
is a region-specific questionnaire that assesses disability, including a question about pain. 
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questionnaire like the other included outcomes, as opposed to a disease-specific outcome 
measure like the WORC.  
There was a statistically significant difference in treatment effect in favour of the palpation 
guided studies (p = 0.01) (Fig. 6). However, heterogeneity of the group differences was high 
with I2 = 83.5%. We attempted to reduce the heterogeneity by further subgroup analyses of a 
priori hypotheses for heterogeneity, but we were unable to adequately reduce I2 to below the 
maximum 60% threshold. For example, the heterogeneity decreased to 62.2% with a p = 0.10 
when we removed the sham and placebo studies. The removal of either low or high 
concentrations of PRP also did not change the heterogeneity. Additional comparison of the raw 
scores of disability and functional outcomes at six months produced a non-significant difference 
of treatment effect (p = 0.16) with a moderately low I2 of 48.5%.   
 
Figure 6 Comparison of change in scores from baseline for the ultrasound (US) versus 
palpation (non-US) guided injections of PRP using disability and functional outcomes at six 
months follow up. 
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 Discussion 
 Summary of evidence 
There are currently no published studies directly comparing the effectiveness of ultrasound 
versus palpation guided injections of PRP in musculoskeletal pathologies. In our systematic 
review and meta-analysis we compared these two techniques of PRP injection using an indirect 
analysis method. There was no significant difference in failure rates between ultrasound and 
palpation guided injections or for pain at less than two months, two to three months, or six 
months follow up. We found a significant difference between treatment groups in favor of 
palpation guided injections for disability and functional outcomes at six months follow up, 
however, there was high heterogeneity between treatment groups and therefore superiority of the 
palpation guided injection could not be definitively concluded.  
We hypothesized that the administration of a PRP injection using ultrasound guidance would 
result in better outcomes. However, our results do not support this theory. Thus, there is no 
evidence to support the additional cost of equipment and the expertise required to perform 
injections under ultrasound guidance.  
 Limitations 
The studies included in our systematic review and meta-analyses reiterated the need for higher 
powered and more rigorous randomized controlled trials to determine the effectiveness of PRP. 
The high levels of heterogeneity we found in our statistical analyses of disability and functional 
outcomes may be reflective of the intrinsic treatment and methodological variations within the 
included studies. 
There were six different types of PRP preparation systems used, contributing to the heterogeneity 
of studies. These systems varied the speed and frequency of the spinning process, and the 
method for extraction (some maintain the leukocytes or buffy layer, while others do not)37,53,62  
Furthermore, the different preparation systems yielded varying concentrations of PRP, ranging 
between two to six times higher than baseline blood. There is currently no standardized 
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concentration of platelets deemed essential for the effectiveness of PRP, adding to the 
heterogeneity of the treatment effect. 
Additionally, the inclusion or omission of an anticoagulant, buffer, and/or an activator during the 
PRP preparation varied between studies and preparation systems. This also affected the 
concentration of platelets and associated growth factors, and may have introduced another cause 
for heterogeneity among treatment effect and study results.  
The number of injections among studies ranged from one to as high as eight in one study12, with 
most studies performing between one or two as part of the treatment protocol. There is still no 
consensus on the number of injections recommended for PRP treatment.  
Five of the studies15,38,39,41,47,54,57,65,66  included in our review received direct sponsorship, or were 
provided some form of compensation toward the study or author. Djulbegovic et al.67 examined 
the quality of 136 studies evaluating the effectiveness of treatments in multiple myeloma and 
found that RCT’s funded solely or in part by industry had a significantly greater effect of new 
treatments compared to studies funded by government or non-profit organizations. The reporting 
of results for these studies may have biased our analysis and contributed to the overall 
heterogeneity of the systematic review.   
Finally, 1111,12,37,41,48,51,53,55,59–61 of the included studies had a total sample size equal to or less 
than 30. Low sample sizes contribute greatly to the probability of Type II error, where the 
variability is still too great to statistically detect a sizable treatment effect and to Type I error 
whereby random sampling error captures larger treatment effects than truly exist in the 
population. 
 Conclusions 
There is currently no evidence to support the use of ultrasound to guide needle placement when 
injecting PRP for resolution of symptoms from palpable tendon or muscle structures in 
musculoskeletal pathologies.  
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Chapter 4 A Randomized Double-blind Clinical Trial to evaluate 
the use of Platelet-rich Plasma versus Corticosteroid Injection in 
Plantar Fasciitis 
 Abstract 
Background: Plantar fasciitis is a chronic, degenerative breakdown of the plantar fascia that 
spans the sole of the foot. The pathology is associated with point tenderness at the medial side of 
the heel and pain and tightness with weight bearing. Corticosteroid (CS) injections is a fairly 
common treatment option after other non-operative treatments have failed. Platelet-rich plasma 
(PRP) may optimize the healing environment for tissue regeneration and repair such that an 
injection of PRP, may provide greater improvements in pain and function than corticosteroid 
injections. 
Purpose: To compare the pain, function and quality of life in patients who have received a PRP 
injection versus a corticosteroid injection for the treatment of plantar fasciitis. 
Methods: We conducted a randomized controlled trial (RCT) in patients with plantar fasciitis 
who were referred to our clinic from local primary care physicians. Patients were stratified by 
symptom duration (less than and greater than three months) and received either a PRP or CS 
injection. We measured outcomes at two weeks, six weeks, three months, six months and one 
year. Our primary outcome was the AOFAS ankle-hindfoot scale; secondary outcomes included 
the SF-12v2® Health Survey and the Plantar Fasciitis Pain and Disability (PFPD) scale. 
Results: We screened 159 patients, of which 133 were eligible and randomized (PRP = 66, CS = 
67). For the purpose of this thesis we included 114 patients in the analysis (PRP = 57, CS = 57). 
At six months the mean and standard deviation of the AOFAS Ankle-hindfoot scale was 
67.1±18.3 for the PRP group and 70.8±17.6 for the CS group (mean difference -1.7, CI -7.6 to 
4.2, p = 0.6). At one year the mean and standard deviation was 72.3±19.1 for the PRP group and 
75.6±17.0 for the CS group (mean difference -1.3 CI -7.3 to 4.6, p = 0.7). We also found no 
statistically significant differences between treatment groups for any of the secondary outcome 
measures (p > 0.05). 
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Conclusion: PRP does not provide greater self-reported pain relief or function than CS 
injections in patients with plantar fasciitis. 
 Introduction 
Plantar fasciitis is a chronic, degenerative breakdown of the plantar fascia, most commonly at its 
origin of the calcaneus. Injury of the structure is commonly caused by repetitive strain during 
locomotion which creates microtears of the fibers, and may include an inflammatory and 
associated repair response of the tissue1,2.  
Clinical diagnosis of plantar fasciitis includes patient complaint of point tenderness and pain in 
the medial plantar heel area of the foot with weight bearing3. The pain is especially severe during 
the first few steps in the morning, decreases with rest, and is exacerbated with prolonged weight 
bearing activities4,5. Ultrasound imaging has shown a thickening of the plantar fascia on the 
involved side by greater than 4mm compared to the uninvolved side in patients who are 
symptomatic6. 
More than one million individuals present to outpatient clinics with plantar fasciitis each year7. 
Approximately 30% of patients with plantar fasciitis will have bilateral pain, and 50% present 
with heel spurs which may or may not be symptomatic5,8. Although conservative treatment has 
been shown to be successful  in 90% of patients, symptoms may last as long as six to 12 months 
before relief is attained obtain people afflicted with this disease can expect to have symptoms as 
long as six to 12 months5,8,9. 
The pathology is most prevalent in patients aged 45-64 years old, and more so in women than 
men7. Plantar fasciitis often presents in individuals with increased tensile load on the plantar 
fascia, such as running athletes or people with occupations that require prolonged standing. Poor 
biomechanics and anatomical variation, such as pes planus (flat feet) and pes cavus (high arches) 
are common predisposing factors to plantar fasciitis4,5.   
More than 80% of patients find symptom relief with non-operative care1,10 including, 
physiotherapy, non-steroidal anti-inflammatory drugs, shoe orthotics or heel pads, night splints, 
shockwave therapy, and injections4,5,9. A corticosteroid (CS) injection may also be offered but 
usually only after failure of other non-operative treatments.  
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Corticosteroid injection is the current standard of treatment for patients who are resistant to acute 
treatment (ie. physical therapy). Current literature supports its use for short-term relief of pain. 
However, adverse events – including fat pad atrophy and rupture of the plantar fascia – have 
been linked to successive corticosteroid injections5,8,11,12. 
Li et al13 conducted a systematic review and meta-analysis of studies that evaluated the efficacy 
of CS injections compared to a placebo for plantar fasciitis. They included four randomized 
controlled trials with a total 289 patients and reported a significant improvement of VAS pain 
scores in favour of the CS group at one month (p < 0.05), but no difference was found between 
treatments at two or three months post injection (p > 0.05). There was also no difference between 
treatments for the improvement of plantar fascia thickness (p > 0.05) on ultrasound evaluation. 
Given the adverse event profile of CS, it would be useful to find a safe and effective alternative. 
Platelet-rich plasma (PRP) injections have emerged as a promising new treatment that may offer 
improved symptom relief compared to CS injections for patients with plantar fasciitis14. PRP is 
obtained through the centrifugation of human blood, which results in a high concentration of 
platelets suspended in plasma15. Platelets are rich in growth factors essential to the healing 
process of tissue. The injection of PRP into injured tissue is theorized to optimize the ideal 
healing environment for tissue regeneration and repair16. 
Hsiao et al17 conducted a meta-analysis to compare the effectiveness of autologous blood-derived 
products (ABP’s) (included PRP treatment), shockwave therapy, and CS injections for the 
treatment of plantar fasciitis. They included seven RCT’s and three quasi-experimental studies 
for a total of 604 patients. There was no significant differences between the three treatment 
groups for VAS pain scores at three and six months post treatment (p > 0.05), but a subgroup 
analysis of PRP studies (other ABP’s removed) versus CS treatments at three months revealed a 
significant improvement of VAS pain scores in the PRP compared to CS treatments at (p < 0.05).  
Finally, Franceschi et al18 conducted a systematic review to evaluate the effectiveness of PRP in 
the treatment of plantar fasciopathy. The review included eight studies: three RCT’s, one cohort 
study, and four prospective case series. In the first RCT19 comparing PRP (n = 10) to dextrose 
prolotherapy (n = 11), they found no significant difference between groups (p > 0.05) at two and 
six months for pain, disability, and activity limitation measured using the Foot Functional Index . 
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The second RCT20 compared PRP (n = 15) to CS injections (n = 15) using the VAS pain scale 
and the Foot Health Status questionnaire at six weeks. The authors reported a statistically 
significant difference between treatments for both outcomes (p < 0.05) in favor of PRP. The third 
RCT21 also compared PRP (n = 20) to a CS injection (n = 20) at three, six, 12 and 24 months 
follow up. The authors found a statistically significant improvement in AOFAS hindfoot scores 
in favor of the PRP group at each follow up over the two years patients were followed (p < 0.05). 
The prospective cohort study22 compared PRP (n = 30) to CS (n = 30) injection using the VAS 
pain scale and the Roles and Maudsley score, a pain and activity limitations scale, at three and 
six months follow up. They found no statistically significant difference between groups (p > 
0.05). The results of the systematic review suggest promising results for PRP as a treatment for 
plantar fasciitis, however, a methodologically rigorous randomized controlled trial with a large 
sample size will provide greater certainty about the superiority of PRP.      
Therefore, we conducted a RCT in which we compared the effectiveness of PRP versus CS 
injections in patients with plantar fasciitis. We hypothesized that PRP may offer a greater 
reduction in pain and lead to improved function in patients with plantar fasciitis. 
 Methods 
 Study Design 
Our study was a RCT that randomized patients to one of two groups (PRP or CS injection)  using 
a computer-generated 1:1 randomization scheme, in permuted blocks of two and four, with 
stratification by duration of symptoms (< six months versus ≥ six months). The investigating 
physician, patient, and outcome assessor were all blinded to group allocation. Blood was drawn 
from all included patients by the nurse who then prepared and blinded the syringe prior to 
injection. 
 Patient Selection 
We recruited patients from surrounding family physician offices using advertising posters 
(Appendix 2). Referrals were sent to the office of the investigating physician and patients were 
scheduled for a consultation at our sports medicine clinic. The investigating physician diagnosed 
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the patient with plantar fasciitis if the patient presented with pain with palpation of the medial 
calcaneal insertion of the plantar fascia that was worse in the morning and prolonged weight 
bearing, and subsided with rest.  
Patients with plantar fasciitis were included if they were between the ages of 18 and 70 years and 
were willing to comply with the follow up protocol. Patients were ineligible if they were 
diagnosed with a tendon rupture, neurological or vascular insufficiencies in the painful heel, 
Paget disease or calcaneal fat pad atrophy, osteomyelitis, fracture of the calcaneus, ankle 
inflammation, recent infection in the treatment area, history of rheumatic diseases, collagenosis 
or metabolic disorders, immunosuppressive therapy or coagulation disturbance and/or therapy, 
long-term treatment with CSs, previous surgery of heel, malignant disease, diabetes mellitus, 
severe cardiac or respiratory disease, significant abnormalities in hepatic function.  
The study protocol was explained and written consent was obtained. Our study protocol was 
approved by our institutional research ethics board and the trial was registered at 
clinicaltrials.gov (NCT01614223).  
 PRP and CS Preparation 
All patients were seen at our clinic on Thursday mornings between 8:30am and 1:00pm. Our 
nurse (MY) extracted approximately 12cc’s of blood from the patient’s arm, which was then 
placed in an Arthrex ACP® double syringe system and spun in a table-top Rotafix 32A 
centrifuge at 1500 rpm for five minutes. This process of centrifugation separated the blood into a 
visible three-layer consistency of red blood components (bottom), a very thin, milky white 
leukocyte component (middle), and yellow plasma components (top). The nurse then extracted 
only the plasma from the top layer (between three and 4cc’s) and blinded the syringe using 
opaque tape. The remaining fluid was discarded appropriately.  
For the CS group, we added 2cc’s of 2% Xylocaine to the 1cc solution of Celestone to 
equilibrate the weight with the PRP treatment to maintain blinding of the investigating physician. 
The CS solution was prepared in an opaquely blinded syringe identical to the size of the smaller 
syringe used in the Arthrex ACP® double syringe system.  
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 Injection Method 
We used the same method of injection for both the ACP® and CS treatments. The investigating 
physician (KW) palpated the point of most tenderness and marked the spot. The plantar surface 
and heel of the involved foot was then sterilized and prepped for injection. A local analgesic, 
Lidocaine (2% concentration) was injected superficially into the area. This was followed 
immediately by the ACP® or CS injection into the marked spot. If patients indicated that they 
had excessive pain three months after the first injection, we offered a second injection of the 
group allocated treatment.  
 Outcome Measures and Follow Up 
Our primary outcome measure was the American orthopaedic foot and ankle society (AOFAS) 
scale. The AOFAS scale is a validated and reliable region-specific, quality of life and objective 
functional scale23–25. It is a combination of a patient-reported grading of pain, functional ability 
during activities of daily living, and physician assessed range of motion (ROM), stability, and 
ankle alignment. The scale is scored as an overall total out of 100, where a score of 100 
represents the best possible outcome.  
Secondary outcome measures included the Plantar Fasciitis Pain and Disability (PFPD) scale and 
the SF-12v2® Health Survey. The PFPD is a disease-specific pain and disability scale that has 
shown comparative validity and reliability with the Foot Function Index (FFI) and the visual 
analogue pain scale (VAS)26,27. The SF-12v2® is a well-known generic quality of life scale28.  
 Sample Size Calculation 
Based on the ability to detect a moderate effect size of 0.5 with 80% statistical power and 0.05 
type one error, we calculated a sample size of 64 patients per group. To account for a drop-out 
rate of 10% we recruited a final sample size of 70 patients per treatment group. 
 Statistical Analysis 
We followed the intention-to-treat (ITT) principle. We calculated the adjusted mean, adjusted 
between-group mean difference with 95% confidence interval, and associated probability values. 
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We used an analysis of covariance (ANCOVA) to analyze the primary outcome where the 
dependent variable was the AOFAS score at six months and one year post-treatment, the 
independent variable was the treatment group and the covariate was the baseline AOFAS score. 
We used the same analysis for the secondary outcomes. For patients with missing data points 
between visits we used regression to impute missing values. We included the last outcome 
carried forward (LOCF) in the analysis for patients who were lost to follow up. We determined 
the minimal clinically important difference (MCID) for all outcome measures as a between 
group difference of 20%29. We calculated a within-groups MCID by calculating the pooled 
standard deviation (SD) of the treatment groups at baseline, multiplied this value by a moderate 
effect size of 0.5. We then converted this value into a between-groups MCID by multiplying the 
within-groups MCID by 0.2 as described by Goldsmith et al29.  
 Results 
For the purpose of this thesis paper, we analyzed the data of patients who were at least 1 year 
post intervention (n=114). Between 2010 and 2015, 159 patients were screened for eligibility. Of 
these, 24 were ineligible: 11 did not have plantar fasciitis, eight did not want to be randomized, 
four had a concomitant disease, and one received a steroid injection two weeks prior to the 
baseline visit. Therefore a total of 133 patients were eligible, gave consent, and were randomized 
into treatment groups (Fig. 7).  
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Figure 7 Study patient flow diagram of treatment groups. 
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66 
 
Treatment groups were balanced for baseline demographics (Table 8). Independent groups t tests 
showed no statistically significant differences between treatment groups for baseline scores of 
the AOFAS ankle-hindfoot scale, SF12, and PFPD questionnaire (Table 9 and Fig. 8). 
Demographic ACP® Group 
n =  57 
CS Group 
n = 57 
Age (years) 52 ± 11 48 ± 9  
Height (cm) 168 ± 12 168 ± 14 
Weight (kg) 88 ± 18 84 ± 18 
Sex (% Male) 25 (44%) 19 (33%) 
Symptom duration (months) 37 ± 62 32 ± 63 
Affected side: 
   Right 
   Left 
   Both 
 
20 (35%)  
32 (56%)  
5 (9%) 
 
29 (51%)  
26 (46%)  
2 (4%) 
Foot alignment 
   Cavus 
   Planus 
   Neutral 
 
9 (16%) 
6 (11%) 
42 (74%) 
 
8 (14%) 
11 (19%) 
38 (67%) 
Smoker 16 (28%) 16 (28%) 
Previous treatments: 
 Physical therapy 
 Orthoses: 
Over the counter 
Custom 
Taping or heel pads 
Shoe modification 
Night splints 
Topical analgesic or NSAIDs 
Prescription analgesics or NSAIDs 
Local anaesthetic injection 
Electrocorporeal shockwave therapy 
Corticosteroids 
Other (acupuncture, cast, massage, 
weight loss, laser therapy) 
  
36 (63%) 
42 (74%) 
5 (9%) 
37 (65%) 
20 (35%) 
7 (12%) 
13 (23%) 
9 (16%) 
9 (16%) 
2 (4%) 
8 (14%) 
13 (23%) 
0 
  
36 (63%) 
40 (70%) 
4 (7%) 
36 (63%) 
18 (32%) 
12 (21%) 
19 (33%) 
11 (19%) 
19 (33%) 
3 (5%) 
9 (16%) 
17 (30%) 
9 (16%) 
Table 8 Pre-intervention demographics for randomized patients. Values represent the mean 
± standard deviation for variables measured using a continuous scale and the number and 
proportion for variables measured using a dichotomous scale. 
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 Primary outcome 
4.4.1.1 AOFAS 
We found no statistically significant difference between treatment groups for improvement in 
pain and function for the AOFAS Ankle-hindfoot scale at six months or one year follow up. The 
adjusted mean differences were -1.7 (CI -7.6 to 4.1, p = 0.57) at six months and -1.3 (CI -7.3 to 
4.6, p = 0.66) at one year.  
 ACP® CS MD (95% CI) p value 
AOFAS 
   Baseline 
   2 weeks 
   6 weeks 
   3 months 
   6 months 
   1 Year 
 
53.5±2.6 
60.9±1.7 
64.4±2.0 
65.1±1.9 
68.1±2.1 
73.3±2.1 
 
57.8 ± 2.6 
64.3±1.7 
64.3±2.0 
67.1±1.9 
69.8±2.1 
74.6±2.1 
 
-4.3 (-11.4 to 2.9) 
-3.4 (-8.1 to 1.4) 
0.1 (-5.5 to 5.7) 
-2.0 (-7.4 to 3.3) 
-1.7 (-7.6 to 4.1) 
-1.3 (-7.3 to 4.6) 
 
0.24 
0.16 
0.96 
0.46 
0.57 
0.66 
PFPD 
Baseline 
2 Weeks 
6 Weeks 
3 Months 
6 Months 
1 Year 
 
63.4±1.6 
54.2±1.7 
49.0±2.2 
46.8±2.3 
41.4±2.8 
33.5±2.6 
 
60.1±1.6 
50.5±1.7 
47.8±2.2 
45.8±2.3 
42.1±2.8 
36.3±2.6 
 
3.3 (-1.2 to 7.8) 
3.8 (-0.9 to 8.5) 
1.2 (-4.9 to 7.3) 
0.9 (-5.5 to 7.3) 
-0.7 (-8.7 to 7.2) 
-2.8 (-10.1 to 4.5) 
 
0.15 
0.12 
0.70 
0.78 
0.86 
0.45 
SF12 PCS 
Baseline 
2 Weeks 
6 Weeks 
3 Months 
6 Months 
1 Year 
 
40.8±1.3 
42.7±0.8 
42.8±0.9 
43.9±1.0 
44.5±1.1 
46.9±1.1 
 
42.1±1.3 
44.3±0.8 
44.2±0.9 
44.3±1.0 
45.3±1.1 
46.7±1.1 
 
-1.4 (-4.9 to 2.2) 
-1.7 (-3.9 to 0.6) 
 1.3 (-3.9 to 1.2) 
-0.5 (-3.4 to 2.5) 
-0.8 (-3.8 to 2.2) 
 0.2 (-2.9 to 3.2) 
 
0.44 
0.15 
0.29 
0.76 
0.61 
0.91 
SF12 MCS 
Baseline 
2 Weeks 
6 Weeks 
3 Months 
6 Months 
1 Year 
 
48.9±1.6 
49.9±0.9 
50.4±1.0 
50.1±1.0 
51.7±1.1 
52.3±1.1 
 
49.6±1.6 
48.6±0.9 
49.5±1.0 
49.9±1.0 
50.5±1.1 
51.4±1.1 
 
-0.7 (-5.3 to 3.9) 
1.3 (-1.1 to 3.7) 
0.9 (-1.9 to 3.8) 
0.2 (-2.8 to 3.1) 
1.2 (-1.8 to 4.2) 
0.9 (-2.2 to 4.1) 
 
0.76 
0.27 
0.51 
0.92 
0.43 
0.57 
Table 9 AOFAS Ankle-hindfoot scale, Plantar Fasciitis Pain and Disability scale (PFPD), 
and SF12 Physical and Mental Component Summary (PCS and MCS) adjusted scores 
(mean ± standard error). Negative values are in favour of CS injections. MD = mean differ. 
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Figure 8 Unadjusted means and confidence intervals (error bars) for the AOFAS outcome 
measure over time. B = baseline, wk = week, m = month, yr = year 
 Secondary outcomes 
4.4.2.1 Plantar Fasciitis Pain and Disability (PFPD) 
We found no statistically significant difference between treatment groups for the disease-specific 
PFPD scale at six months or one year. The adjusted mean differences were -0.73 (CI -8.68 to 
7.22, p = 0.86) at six months and -2.78 (CI -10.1 to 4.54, p = 0.45) at one year. 
4.4.2.2 SF12 Physical Component  
We found no statistically significant difference between treatment groups for the physical 
component score of the SF12 at six months or one year. The adjusted mean differences were -0.8 
(CI -3.8 to 2.2, p = 0.61) at six months and 0.2 (CI -2.9 to 3.2, p = 0.91) at one year.  
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4.4.2.3 SF12 Mental Component 
We found no statistically significant difference between treatment groups for the mental 
component score of the SF12 quality of life outcome measure at six months or one year. The 
adjusted mean differences were 1.2 (CI -1.82 to 4.22, p = 0.43) at six months and 0.92 (CI -2.24 
to 4.08, p = 0.57) at one year 
 Adverse Events and Second Injection 
Three patients in the ACP® group each received a second injection at three, six, and 12 months 
respectively. Two patients in the CS group received a second injection at six months. One patient 
in the CS group and one patient in the PRP had complete pain relief in the affected limb and 
requested the same injection on the contralateral foot. One patient in the CS group and three 
patients in the ACP® group had unresolved pain at the end of the study. One patient in the CS 
group ruptured their plantar fascia six months after completing the study. 
 Discussion 
Chronic plantar heel pain is a debilitating condition that has a significant negative impact on both 
foot-specific and general health-related quality of life30. For patients who find no relief from 
non-operative care, injection therapy of steroids or autologous blood products may offer some 
relief of symptoms and promote healing3,4,31. In our study we found no statistically significant 
difference between injections of CS or PRP in the amount of improvement in self-reported pain 
and function as measured by the AOFAS Ankle-hindfoot scale in patients with plantar fasciitis. 
Secondary outcomes were also not significantly different between treatment groups.  
The 95% confidence intervals around the mean difference for each outcome do not rule out the 
possibility that PRP is superior to CS.  However, we can be certain that if there is a benefit of 
PRP, the difference not likely to be large and therefore is not likely to justify the cost. 
On the other hand, CS injections in patients struggling with plantar fasciitis have not shown long 
term superior effectiveness compared to placebos13 and repeated use of CS in tendons has been 
associated with adverse effects such as plantar fascia rupture and/or fat pad atrophy32–34. In our 
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study, one patient in the CS group had a rupture of their plantar fascia six months after their one 
year follow up.  Thus, if PRP can offer similar benefits to CS without the added risk of tendon 
degeneration, it may offer a reasonable alternative to an injection of CS. 
PRP is theorized to create an environment essential for healing tissue through the release of 
growth factors from platelets when the cells become activated during clotting. The collective 
body of literature evaluating the effectiveness of PRP compared to CS injections for patients 
with plantar fasciitis contains a range of different preparation systems with individualized 
preparation methods used to create the PRP35–37. This results in varying concentrations of 
platelets and may obscure the overall treatment effect. Additionally, there is a lack of well-
designed RCT’s with standardized outcomes and long term follow ups to support the conclusive 
evidence of the comparison between PRP and CS injections for plantar fasciitis. 
In the network meta-analysis by Franceshi et al18 that compared PRP versus other injections in 
patients with plantar fasciitis, authors included three RCT studies, and three comparative cohort 
studies. The total number of participants included in each study ranged from 30 to 61 patients 
whereas our study included almost double (n = 114) the number of patients compared to the 
study with the most participants. Two of the included studies were single-blind and the rest did 
not use blinding whereas we were able to blind the patient, physician, and outcomes assessor to 
group allocation. The maximum follow up period with the included studies was six months post-
injection, whereas our study followed patients up to one year after treatment. For these reasons, 
we are confident that our conclusions represent the most rigorous findings to date.   
Another recently published study38 comparing the effectiveness of PRP (n = 25) versus CS (n = 
25) injections in patients with plantar fasciitis, compared treatment groups at six weeks and six 
months using the VAS pain scale and the AOFAS scale. Authors found a statistically significant 
difference between groups for all outcomes at both follow up periods (p < 0.05) in favour of 
PRP.  In evaluating the internal validity of the study, patients chose which treatment they 
preferred and were then allocated into groups accordingly. Although the groups were balanced 
for baseline demographics, the omission of randomization may have introduced a selection bias 
and influenced the results.    
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Shetty et al39 also published the preliminary results of a non-randomized trial where authors 
compared PRP (n = 30) versus CS (n = 30) injections in patients with plantar fasciitis. The 
groups were compared at three months after the injection using the VAS pain scale, the Foot and 
Ankle Disability Index (FADI), and the AFAS. The authors found a statistically significant 
improvement of scores in favor of PRP for all outcomes at three months (p < 0.05). The process 
of group allocation was not described and no method of blinding was implemented. 
 Study Limitations 
In our study, patients were allowed to add other forms of non-operative management (e.g. 
orthotics, laser therapy, massage, physiotherapy, etc.) for plantar fasciitis to their treatment 
regimen, with the exception of injections which made our study more pragmatic and applicable 
to regular practice where patients seek a variety of treatment options for plantar fasciitis. 
However, we did record the number of patients who sought physiotherapy during the study 
treatment period and found that they were balanced between groups (ACP® = 23, CS = 25). 
The study was performed at a single-centre with a single surgeon performing all injections. 
Although the surgeon is a fellowship-trained physician with many years of experience, the 
addition of other centres and physicians may have added to the generalizability of the results.  
We did not perform any ultrasound diagnostic evaluation of the plantar fascia to compare the 
thickness before and after treatment. Plantar fasciitis is known to be associated with a thickening 
of the plantar fascia40, and evaluation of the improvement of the thickness between treatment 
groups may have been a useful tool. 
We did not have a placebo group in our study, which limited our ability to make inferences about 
its superiority to no treatment at all. However, since we were trying to determine whether ACP 
could replace CS as a treatment for plantar fasciitis (given its adverse event profile), if we could 
show that ACP was similar or superior to corticosteroids then it is not necessary to compare ACP 
to placebo. 
Individual variations of platelet concentration may have different effects on treatment 
outcomes43. Although we did not evaluate the concentration of platelets achieved for each 
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injection, other studies44 conducted by this same group demonstrated consistent concentrations 
between two and three times greater than baseline blood which has been shown to be 
effective41,42. 
Despite meeting our a priori sample size requirements, our confidence intervals were too wide to 
allow definitive conclusions about the superiority of ACP® compared to CS). However, we can 
be certain that if there is a benefit of ACP® over CS that the effect is small; thus it is reasonable 
to adopt ACP® as part of usual treatment option prior to administration of CS43.  The only other 
consideration is the cost to the patient and whether it is covered by public or third-party funding. 
PRP preparation systems produce either leukocyte-rich (LR) or leukocyte-poor (LP) PRP. 
Leukocytes contain and produce cytokines which promote catabolic (molecular breakdown) 
cellular activity and inflammation44 which is counteractive to the anabolic  actions of the growth 
factors released by platelets in PRP. Thus, one expects that reduced leukocyte levels within a 
PRP solution may have a more positive effect on healing than leukocyte-rich PRP44,45. The 
presence or absence of inflammation in the damaged tissue is influential to the process of 
healing46. In acute pathologies where initial inflammatory activity is occurring at the site of 
tissue damage, additional leukocyte promotion may not be beneficial. However, in chronic 
conditions where the inflammatory process has subsided or no longer occurs, the addition of 
leukocytes may be advantageous in stimulating the initial healing process47. Plantar fasciitis has 
recently been redefined to classify the condition as plantar fasciosis when the symptoms are 
chronic without inflammation2. The absence of inflammation in the damaged tissue causes the 
healing response to include less inflammatory cellular activity than in an acute condition. For 
this reason, the ideal PRP solution for plantar fasciitis, given that it is a chronic condition, may 
need to include leukocytes to stimulate the necessary inflammatory response for healing to take 
place48. The ACP® solution used in our study did not contain leukocytes. 
 Future Directions 
Directions for future research into the effectiveness of PRP injections in patients with plantar 
fasciitis should include a standardized physiotherapy, and the use of a PRP treatment that 
includes leukocytes. Plantar fasciitis is a chronic condition that is not always associated with 
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inflammation2 and the presence of leukocytes which is known to promote inflammation may 
work in favor of creating the natural healing environment for the fascia. 
 Conclusion 
We found no evidence thatACP is inferior to CS in patients with plantar fasciitisGiven the 
adverse event profile of CS it is reasonable for clinicians to use ACP prior to CS. 
  
74 
 
 
 References 
1.  Schepsis A a., Leach RE, Gouyca J. Plantar Fasciitis. Clin Orthop Relat Res. 
1991;&NA;(266):185???196. doi:10.1097/00003086-199105000-00029. 
2.  Lemont H, Ammirati KM, Usen N. Plantar fasciitis: a degenerative process (fasciosis) 
without inflammation. J Am Podiatr Med Assoc. 2003;93(3):234-237. 
3.  Glazer JL. An approach to the diagnosis and treatment of plantar fasciitis. Phys 
Sportsmed. 2009;37(2):74-79. doi:10.3810/psm.2009.06.1712; 10.3810/psm.2009.06.1712. 
4.  Gill L. Plantar Fasciitis: Diagnosis and Conservative Management. J Am Acad Orthop 
Surg. 1997;5(2):109-117. http://www.ncbi.nlm.nih.gov/pubmed/10797213. 
5.  Neufeld SK, Cerrato R. Plantar fasciitis: evaluation and treatment. J Am Acad Orthop 
Surg. 2008;16(6):338-346. 
6.  Argerakis NG, Positano RG, Positano RCJ, et al. Ultrasound Diagnosis and Evaluation of 
Plantar Heel Pain. 2015;105(2):135-140. 
7.  Riddle DL, Schappert SM. Volume of ambulatory care visits and patterns of care for 
patients diagnosed with plantar fasciitis: a national study of medical doctors. Foot ankle Int / Am 
Orthop Foot Ankle Soc [and] Swiss Foot Ankle Soc. 2004;25(5):303-310. 
doi:10.1177/107110070402500505. 
8.  Roxas M. Plantar fasciitis: diagnosis and therapeutic considerations. Altern Med Rev. 
2005;10(2):83-93. 
http://go.galegroup.com.proxy1.lib.uwo.ca/ps/i.do?id=GALE|A133904354&sid=summon&v=2.1
&u=lond95336&it=r&p=AONE&sw=w&asid=e82afee6163404567ac18a359fd3b91e. 
9.  Thomas JL, Christensen JC, Kravitz SR, et al. The Diagnosis and Treatment of Heel 
Pain: A Clinical Practice Guideline-Revision 2010. J Foot Ankle Surg. 2010;49(3):S1-S19. 
doi:10.1053/j.jfas.2010.01.001. 
75 
 
10.  Davis PF, Severud E, Baxter DE. Painful heel syndrome: results of nonoperative 
treatment. Foot ankle Int. 1994;15(10):531-535. 
11.  Tatli YZ, Kapasi S. The real risks of steroid injection for plantar fasciitis, with a review 
of conservative therapies. Curr Rev Musculoskelet Med. 2009;2(1):3-9. doi:10.1007/s12178-
008-9036-1. 
12.  Crawford F, Atkins D, Young P, Edwards J. Steroid injection for heel pain: Evidence of 
short-term effectiveness. A randomized controlled trial. Rheumatology. 1999;38(10):974-977. 
doi:10.1093/rheumatology/38.10.974. 
13.  Li Z, Yu A, Qi B, et al. Corticosteroid versus placebo injection for plantar fasciitis: A 
meta-analysis of randomized controlled trials. Exp Ther Med. 2015. doi:10.3892/etm.2015.2384. 
14.  Raeissadat SA, Sedighipour L, Rayegani SM, Bahrami MH, Bayat M, Rahimi R. Effect 
of platelet-rich plasma (PRP) versus autologous whole blood on pain and function improvement 
in tennis elbow: A randomized clinical trial. Pain Res Treat. 2014;2014. 
doi:10.1155/2014/191525. 
15.  Aydin F, Pancar Yuksel E, Albayrak D. Platelet collection efficiencies of three different 
platelet-rich plasma preparation systems. J Cosmet Laser Ther. 2015;17(3):165-168. 
doi:10.3109/14764172.2014.1003237. 
16.  de Vries RA, de Bruin M, Marx JJ, Hart HC, Van de Wiel A. Viability of platelets 
collected by apheresis versus the platelet-rich plasma technique: a direct comparison. Transfus 
Sci. 1993;14(4):391-398. 
http://sfx.scholarsportal.info/western?sid=OVID:medline&id=pmid:10146646&id=doi:&issn=09
55-3886&isbn=&volume=14&issue=4&spage=391&pages=391-
8&date=1993&title=Transfusion+Science&atitle=Viability+of+platelets+collected+by+apheresi
s+versus+the+platelet-rich. 
17.  Hsiao M-Y, Hung C-Y, Chang K-V, Chien K-L, Tu Y-K, Wang T-G. Comparative 
effectiveness of autologous blood-derived products, shock-wave therapy and corticosteroids for 
76 
 
treatment of plantar fasciitis: a network meta-analysis. Rheumatology. 2015;(87). 
doi:10.1093/rheumatology/kev010. 
18.  Franceschi F, Papalia R, Franceschetti E, Paciotti M, Maffulli N, Denaro V. Platelet-rich 
plasma injections for chronic plantar fasciopathy: a systematic review. Br Med Bull. 
2014;112(1):83-95. doi:10.1093/bmb/ldu025. 
19.  Kim E, Lee JH. Autologous Platelet-Rich Plasma Versus Dextrose Prolotherapy for the 
Treatment of Chronic Recalcitrant Plantar Fasciitis. PM R. 2014;6(2):152-158. 
doi:10.1016/j.pmrj.2013.07.003. 
20.  Omar AS, Ibrahim ME, Ahmed AS, Said M. Local injection of autologous platelet rich 
plasma and corticosteroid in treatment of lateral epicondylitis and plantar fasciitis: Randomized 
clinical trial. Egypt Rheumatol. 2012;34(2):43-49. doi:10.1016/j.ejr.2011.12.001. 
21.  Monto RR. Platelet-Rich Plasma Efficacy Versus Corticosteroid Injection Treatment for 
Chronic Severe Plantar Fasciitis. Foot Ankle Int. 2014;35(4):313-318. 
doi:10.1177/1071100713519778. 
22.  Akşahin E, Doğruyol D, Yüksel H, et al. The comparison of the effect of corticosteroids 
and platelet-rich plasma (PRP) for the treatment of plantar fasciitis. Arch Orthop Trauma Surg. 
2012;132(6):781-785. doi:10.1007/s00402-012-1488-5. 
23.  Goldstein CL, Schemitsch E, Bhandari M, Mathew G, Petrisor BA. Comparison of 
different outcome instruments following foot and ankle trauma. Foot ankle Int / Am Orthop Foot 
Ankle Soc [and] Swiss Foot Ankle Soc. 2010;31(12):1075-1080. doi:10.3113/FAI.2010.1075. 
24.  Ibrahim T, Beiri A, Azzabi M, Best AJ, Taylor GJ, Menon DK. Reliability and validity of 
the subjective component of the American Orthopaedic Foot and Ankle Society clinical rating 
scales. J Foot Ankle Surg. 2007;46(2):65-74. doi:10.1053/j.jfas.2006.12.002. 
25.  SooHoo NF, Vyas R, Samimi D. Responsiveness of the foot function index, AOFAS 
clinical rating systems, and SF-36 after foot and ankle surgery. Foot ankle Int / Am Orthop Foot 
Ankle Soc [and] Swiss Foot Ankle Soc. 2006;27(11):930-934. 
77 
 
26.  Willis B. Pain Scale for Plantar Fasciitis. Foot Ankle Online J. 2009;2(5). 
doi:10.3827/faoj.2009.0205.0003. 
27.  Landorf KB, Radford J a. Minimal important difference: Values for the Foot Health 
Status Questionnaire, Foot Function Index and Visual Analogue Scale. Foot. 2008;18(1):15-19. 
doi:10.1016/j.foot.2007.06.006. 
28.  Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and scoring 
for the SF-12 Health Survey in nine countries: Results from the IQOLA Project. J Clin 
Epidemiol. 1998;51(11):1171-1178. doi:10.1016/S0895-4356(98)00109-7. 
29.  Goldsmith CH, Boers M, Bombardier C, Tugwell P. Criteria for clinically important 
changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and 
trial profiles. OMERACT Committee. J Rheumatol. 1993;20(3):561-565. 
30.  Irving DB, Cook JL, Young M a, Menz HB. Impact of chronic plantar heel pain on 
health-related quality of life. J Am Podiatr Med Assoc. 2008;98(4):283-289. 
31.  Thompson J. Diagnosis and Management of Plantar Fasciitis. J Am Osteopath Assoc. 
2014;114(12):900. doi:10.7556/jaoa.2014.177. 
32.  Kennedy JC, Willis RB. The effects of local steroid injections on tendons: a 
biomechanical and microscopic correlative study. Am J Sports Med. 1976;4(1):11-21. 
33.  Acevedo JI, Beskin JL. Complications of plantar fascia rupture associated with 
corticosteroid injection. Foot ankle Int. 1998;19(2):91-97. 
34.  Leach R, Jones R, Silva T. Rupture of the plantar fascia in athletes. J Bone Joint Surg 
Am. 1978;60(4):537-539. doi:10.1016/S1067-2516(96)80010-X. 
35.  Castillo TN, Pouliot MA, Hyeon JK, Dragoo JL. Comparison of Growth Factor and 
Platelet Concentration From Commercial Platelet-Rich Plasma Separation Systems. Am J Sports 
Med. 2011;39(2):266-271. doi:10.1177/0363546510387517. 
78 
 
36.  Trowbridge W. Platelet Rich Plasma Preparation : A Comparison of the Harvest 
SmartPReP ® 2 APC + ® with the Arthrex ACP TM. 2009;(May):17-18. 
doi:10.1177/0363546506288850. 
37.  Tamimi FM, Montalvo S, Tresguerres I, Blanco Jerez L. A comparative study of 2 
methods for obtaining platelet-rich plasma. J Oral Maxillofac Surg. 2007;65(6):1084-1093. 
http://sfx.scholarsportal.info/western?sid=OVID:medline&id=pmid:17517290&id=doi:&issn=02
78-2391&isbn=&volume=65&issue=6&spage=1084&pages=1084-
93&date=2007&title=Journal+of+Oral+%26+Maxillofacial+Surgery&atitle=A+comparative+stu
dy+of+2+methods+for+obtainin. 
38.  Say F. Comparison of platelet-rich plasma and steroid injection in the treatment of plantar 
fasciitis. ACTA Orthop Traumatol Turc. 2014;48(6):667-672. doi:10.3944/AOTT.2014.13.0142. 
39.  Shetty VD, Dhillon M, Hegde C, Jagtap P, Shetty S. A study to compare the efficacy of 
corticosteroid therapy with platelet-rich plasma therapy in recalcitrant plantar fasciitis: A 
preliminary report. Foot Ankle Surg. 2014;20(1):10-13. doi:10.1016/j.fas.2013.08.002. 
40.  Mahowald S, Legge BS, Grady JF. The correlation between plantar fascia thickness and 
symptoms of plantar fasciitis. J Am Podiatr Med Assoc. 2011;101(5):385-389. 
http://www.ncbi.nlm.nih.gov/pubmed/21957269. 
41.  Choi BH, Zhu SJ, Kim BY, Huh JY, Lee SH, Jung JH. Effect of platelet-rich plasma 
(PRP) concentration on the viability and proliferation of alveolar bone cells: an in vitro study. Int 
J Oral Maxillofac Surg. 2005;34(4):420-424. doi:10.1016/j.ijom.2004.10.018. 
42.  Mastrangelo AN, Vavken P, Fleming BC, Harrison SL, Murray MM. Reduced platelet 
concentration does not harm PRP effectiveness for ACL repair in a porcine in vivo model. J 
Orthop Res. 2011;29(7):1002-1007. doi:10.1002/jor.21375; 10.1002/jor.21375. 
43.  DeLong JM, Russell RP, Mazzocca AD. Platelet-rich plasma: the PAW classification 
system. Arthroscopy. 2012;28(7):998-1009. doi:http://dx.doi.org/10.1016/j.arthro.2012.04.148. 
79 
 
44.  Pratt TM. A Randomized Clinical Trial to Compare the Effect of Non Operative 
Treatment With and Without Autologous Conditioned Plasma ( ACP ) on Healing and Function 
in Patients with Achilles Tendon Ruptures. 2015;(October). 
45.  Smith GD, Morris PE, Fuller RB. Building confidence in confidence intervals. 
2015;28(6):476-479. doi:10.1371/journal.pmed.0020124.K. 
46.  Boswell SG, Schnabel L V., Mohammed HO, Sundman E a., Minas T, Fortier L a. 
Increasing Platelet Concentrations in Leukocyte-Reduced Platelet-Rich Plasma Decrease 
Collagen Gene Synthesis in Tendons. Am J Sports Med. 2013;42(1):42-49. 
doi:10.1177/0363546513507566. 
47.  McCarrel TM, Minas T, Fortier LA. Optimization of leukocyte concentration in platelet-
rich plasma for the treatment of tendinopathy. J Bone Jt Surg - Am Vol. 2012;94(19):e143(1-8). 
doi:http://dx.doi.org/10.2106/JBJS.L.00019. 
48.  Medzhitov R. Origin and physiological roles of inflammation. Nature. 
2008;454(7203):428-435. doi:10.1038/nature07201. 
49.  Dohan Ehrenfest DM, Bielecki T, Jimbo R, et al. Do the fibrin architecture and leukocyte 
content influence the growth factor release of platelet concentrates? An evidence-based answer 
comparing a pure platelet-rich plasma (P-PRP) gel and a leukocyte- and platelet-rich fibrin (L-
PRF). Curr Pharm Biotechnol. 2012;13(7):1145-1152. 
http://sfx.scholarsportal.info/western?sid=OVID:medline&id=pmid:21740377&id=doi:&issn=13
89-2010&isbn=&volume=13&issue=7&spage=1145&pages=1145-
52&date=2012&title=Current+Pharmaceutical+Biotechnology&atitle=Do+the+fibrin+architectu
re+and+leukocyte+content+i. 
50.  Khalafi RS, Bradford DW, Wilson MG. Topical application of autologous blood products 
during surgical closure following a coronary artery bypass graft. Eur J Cardiothorac Surg. 
2008;34(2):360-364. doi:10.1016/j.ejcts.2008.04.026. 
 
80 
 
 
 
5    Chapter 5 Summary 
With an ever ageing population more active later in life, there is a demand for sports pathology 
treatment regimens that can both treat clinical symptoms and provide healing to the injured tissue 
for a continued active lifestyle. An injection of platelet-rich plasma (PRP) into injured tissue is 
theorized to provide an ideal healing environment through the introduction of growth factors 
imperative to tissue regeneration1,2. With improved tissue regeneration and enhanced overall 
healing of the pathology, patients should experience reduced pain, and improved function and 
quality of life. Over the last decade there have been a number of studies evaluating the 
effectiveness of PRP for sports medicine pathologies, however the variation in types of 
pathology, treatment methods, and PRP-specific treatment protocols have clouded the clarity in 
treatment effect. 
Chapter 2: In our systematized review of the literature to evaluate the effectiveness of PRP in 
various tissue-specific pathologies, we found no definitive clinical evidence to support the use of 
PRP. For tendon healing, half of the studies found a significant treatment effect in favor of PRP 
while the other half found no difference. In the two studies we evaluated for the use of PRP in 
bone healing, the studies were again split with one finding a statistically significant effect in 
favor of PRP and the other finding no difference. Again, in muscle healing the two studies we 
evaluated were also split with one finding a significant difference in favor of PRP and the other 
finding no difference. The use of PRP in intra-articular injections of the knee did show some 
encouraging results, particularly in the treatment of osteoarthritis of the knee. We speculate that 
this may be because the PRP provides growth factors in an environment where the damaged cells 
are no longer able to maintain cell reparation through their own growth factor releasing 
mechanism3–5.  
Chapter 3: One area of dispute in the application of PRP injection is whether or not injections 
should be administered using ultrasound to guide needle placement. Proponents of PRP have 
argued that unless the investigator has taken measures to ensure that the PRP was administered 
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to the correct location, that conclusions about effectiveness (especially lack of effectiveness) are 
no more than speculative. To address this controversy, our second systematic review compared 
the effectiveness of PRP in ultrasound versus palpation guided injections for the non-operative 
treatment of tendon and muscle pathologies.  We found no published studies directly comparing 
ultrasound versus palpation guided injections of PRP, which meant that we used an indirect 
analysis to make the comparison. We found no statistically significant differences between 
treatment methods for failure rates or pain scores at less than two months, two to three months, 
and six months post-injection. We did find a statistically significant difference in favor of 
palpation guided injections for functional scores at six months post-injection, but the 
heterogeneity of the comparison was high and so definitive superiority could not be concluded. 
Therefore, we found no evidence to support the claim that ultrasound guided injections of PRP 
offer greater outcomes and the additional cost and inaccessibility of the ultrasound equipment in 
the clinic setting work against its adoption into practice. 
Finally, given the lack of high powered studies and unstandardized PRP preparation methods we 
set out to complete a methodologically rigorous RCT to compare the effectiveness of PRP 
injections compared to corticosteroid (CS) injections in patients with plantar fasciitis. 
Chapter 4: Our study was a computer generated RCT where the patients, the physician 
administering the injection, and the outcomes assessor were blinded. We used the American 
Orthopaedic Foot and Ankle Society (AOFAS) ankle-hindfoot scale, the SF-12v2® Health 
Survey, and the Plantar Fasciitis Pain and Disability scale, all valid and reliable patient-reported 
outcome measures. We had a long term follow up of one year, with interval assessments at two 
weeks, six weeks, three months, and six months after the injection. We had a large sample size of 
114 patients with only a 7% drop out rate. Following our intention-to-treat analysis, we found no 
statistically significant difference for our primary outcome (AOFAS) at six months or one year 
post-injection. In addition, we found no significant difference for any of our secondary outcomes 
at six months or one year. However, confidence intervals around the estimates of effect were 
large and could not rule out the possibility of a beneficial effect of PRP over CS. Our results do 
suggest however, that it is most likely that PRP injection provides similar pain relief and 
functional improvement compared to CS but without the serious side effects observed with CS; 
like tendon rupture which may justify its use. 
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 Regulation of PRP Applications 
In the United States, PRP is regulated by the Food and Drug Administration (FDA) and is 
classified as a Biologic under the Center for Biologics Evaluation and Research (CBER)6. 
Products in this class apply for approval using the 501 (k) application process that allows devices 
that are similar to other already approved devices to be introduced onto the market. The PRP 
preparation systems fall under this category and for this reason the available systems are both 
numerous and vary considerably in the way they are used and in the resulting components of the 
PRP product.  
Originally, PRP systems were approved by the FDA for use in the mixing of the PRP product 
with bone graft materials for orthopaedic surgical use. The transfer of PRP into the clinical 
setting as an injectable treatment, termed “off label”, has become acceptable in North America 
with the understanding that clinicians will use the treatment with self-determined ethical and 
evidential discretion to do no harm. However, controversy has arisen in the use of PRP that uses 
an activator such as thrombin and/or calcium to activate the clotting mechanism during the 
application of PRP7 because this would be in addition to the treatment as initially approved. The 
activator changes the cellular composition of platelets and therefore produces a manipulation of 
the end product.    
The conflict in the regulation of PRP systems has a direct effect on the quality of research and 
resulting evidence to support its use in clinical practice. Since the products approved under the 
501 (k) application do not require evidence from laboratory, animal, and clinical studies, the 
current body of research has not undergone the stringent methodology controls and scrutiny as 
products classified as drugs. The research in the effectiveness of PRP has increased 
tremendously over the past decade, but the validity and reliability of the evidence is 
questionable.  
 Directions for future studies 
The true measure of efficacy for the use of PRP in musculoskeletal pathologies has been diluted 
by the variation in methodology used in the published literature. Future studies evaluating the 
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effectiveness of PRP needs to adhere to certain standardized protocols to be included in a pooled 
collection of results that will provide the necessary evidence to change clinical practice.  
 Choosing a PRP preparation system 
All PRP products are not equal, and comparison of the treatments produced by different systems 
should be considered thoroughly before comparing their effectiveness. For example, when we 
compare two studies with the same pathology and study design, but using different PRP 
preparation systems, one study may produce non-significant results while the other finds a 
statistically significant effect of PRP. This may have been the case in a comparison of our plantar 
fasciitis RCT where we found no significant difference between PRP and corticosteroid 
injections, versus Shetty et al8 in which the authors found a statistically significant difference in 
favor of PRP for similar patient-reported functional outcomes when they also compared PRP to 
corticosteroid injections in patients with plantar fasciitis. In our study we used the ACP Double 
Syringe, Arthrex system which produced a concentration of two to three times higher than 
baseline blood. The other study used the SmartPrep, Harvest Technologies system which is 
known to produce platelet concentrations four to six times greater than baseline levels, and the 
protocol also requires the addition of an anti-coagulant and activator be added. Researchers need 
to focus their efforts on finding the most effective PRP solution for cell types that are important 
in healing the effected structure (e.g. tenocytes, myocytes, chondrocytes, osteocytes), followed 
by measuring the effect of that preparation in a specific tissue type (e.g. tendon, muscle, 
cartilage, bone), and finally, exploring the effectiveness for treating musculoskeletal pathologies 
within a specific patient population. 
 Acute versus chronic conditions 
Tiwari et al9 describes four different types of PRP treatments: leukocyte-poor or pure PRP, 
leukocyte PRP, pure platelet-rich fibrin clot, and leukocyte platelet-rich fibrin clot. All of these 
fall under the collective PRP treatment umbrella, however the solution content, concentration, 
and consistency vary considerably. For musculoskeletal pathologies, the healing of tissue is 
highly dependent on the stage of healing and the body’s natural response of cellular activity and 
differentiation in the area of injury. Acute pathologies are associated with an inflammatory 
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response, whereas chronic conditions are associated with reduced inflammation or the absence of 
inflammation in the area. Since leukocytes are known to cause an inflammatory response in the 
local tissue, and the inclusion or removal of the cells may have a direct effect on the healing 
response of the injured tissue. Therefore, we suggest that investigators consider the stage of 
healing when selecting the type of PRP to treat that particular pathology.  
The fibrin clot is used in the surgical application of PRP. During a surgical procedure the injured 
tissue is repaired and the area begins the acute phases of healing. The PRP solution applied here 
should also be one that should complement the acute healing phase which already includes an 
inflammatory response and may be adversely affected by the addition of leukocytes. 
 Requirements for future studies 
Future research studies evaluating the effectiveness of PRP should include greater detail in the 
PRP preparation method and treatment protocol. This is necessary for the fair comparison across 
studies and valid pooling of data in meta-analyses. The PRP preparation system used, the 
inclusion or exclusion of leukocytes, and the use of anticoagulants and/or activators should be 
specified. The use of image-guidance for injection and a detailed description of how the 
treatment was applied should also be described.  
 Conclusion 
The use of PRP treatments in musculoskeletal pathologies is a promising biological addition that 
should be further explored in clinical trials with higher levels of evidence. Researchers and 
clinicians should consider various aspects of PRP treatment and the options available that will 
produce the most successful treatment for patients in the clinical setting.  
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System 
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Musculoskele
tal Tissue 
Foundation 
RecoverT
M Kit, 
Biomet 
(GPS II 
Platelet 
Separation 
System) 
Magellan, 
Arteriocyt
e 
ACP® 
Double 
Syringe
, 
Arthrex 
PRGF, 
BTI 
Biotechn-
ology 
Institute 
SmartPrep
, Harvest 
Technologi
es 
Pros
ys 
PRP 
Kit 
MyCells® 
Autologou
s Platelet 
Preparatio
n System 
Orthokine®, 
Autologous 
Conditioned 
Serum 
GenesisCS 
Component 
Concentratin
g System 
Platelet 
Concentrat
ion 
1-1.5x 3-8x 3-7x 2-3x 2-3x 4-6x 5-7x 2-3x 2-3x 6-10x 
Anticoagul
ant 
Yes Yes Yes None Yes Yes Yes Yes No Yes 
Centrifuge 
force 
1100g 1100g 1200g 1500rp
m 
460g 400g 1600g 
and 
2000g 
1300 to 
1500rpm 
1000g 2400rpm 
Centrifuge 
time 
(minutes) 
6 15 17 5 8 14 3 10 10 12 
Activator None None None None Yes Yes No No No No 
Spin 
procedure 
Single Single Single Single Single Double Double Single Single Single 
Leukocytes No Yes Yes No No Yes No No No No 
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“ultrasound guided injection” 
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TX “platelet rich plasma” OR “platelet-rich plasma” OR 
“platelet-rich therapy” OR “platelet concentrate” OR 
“platelet gel” OR “growth factor*” OR “autologous plasma” 
OR “plasma rich in growth factor” OR “autologous 
conditioned plasma” OR “regenerative therapy” OR 
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factor” OR “autologous platelet-rich plasma” OR 
“autologous therapy” OR platelet 
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4 (injection or ultrasound or "ultrasound-guided " or "ultrasound  
guided " or "ultrasound-guided injection " or "ultrasound guided  
injection ").af. 
7 tendon.mp. or Tendons/ 
8 2 or 7 
9 3 and 4 and 8 
 
Embase 3632 2. tendon.mp. or tendon injury/ or tendon rupture/ or tendon/ 
3. muscle/ or muscle injury/ or skeletal muscle/ or muscle.mp. 
4. 2 or 3 
8. ("platelet rich plasma" or "platelet-rich plasma" or "platelet-rich 
therapy" or "platelet concentrate" or "platelet gel" or "growth 
factor" or "autologous plasma" or "plasma rich in growth factor" or 
"autologous conditioned plasma" or "regenerative therapy" or 
"platelet-derived growth factor" or "platelet derived growth factor" 
or "autologous platelet-rich plasma" or "autologous therapy" or 
platelet).af. 
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9. (injection or ultrasound or "ultrasound-guided" or "ultrasound 
guided" or "ultrasound-guided injection" or "ultrasound guided 
injection").af. 
10. 4 and 8 and 9 
 
Appendix 3 Systematic review summary of database results 
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